prior treatment with anti neoplastic biologic or chemotherapy for recurrent or metastatic disease except one course of adjuvant immunotherapy and or adjuvant chemotherapy other than <regimen>
no prior temozolomide or polifeprosan 20 with carmustine implant <regimen> for brain metastasis endocrine therapy
v1 1 histologically or cytologically confirmed gi malignancy for which <regimen> is considered an appropriate treatment eg gastric cancer gc colorectal carcinoma pancreatic adenocarcinoma
subject is scheduled to undergo 4 cycles of tc or <regimen> chemotherapy taxotere doxorubicin and cyclophosphamide 75 50 and 600 mg m2 respectively
may have had any prior chemotherapy regimen including any gemcitabine based regimen or <regimen>
progressive disease after at least 1 standard chemotherapy or chemoimmunotherapy regimen eg dacarbazine or <regimen>
all standard <regimen> or <regimen> regimens given on a biweekly schedule will be permitted however 21 day regimens will not be allowed
patients with disease progression with prior <regimen> avastin therapy who are not candidates for primary metastasectomy
patients that achieved a complete cr or partial response pr after 6th r <regimen> chemotherapy
patients with serious pulmonary neurological endocrinological or other disorder interfering with full dosing of <regimen> or fc chemotherapy
patients if enrolled should not receive live vaccine whilst receiving ip and up to 30 days after the last dose of ip vaccination for yellow fever female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of cisplatin
must have received at least one prior cd20 containing multi agent chemotherapy regimen r <regimen> <regimen> bendamustine and rituximab can be the prior regimen if used for follicular lymphoma or marginal zone lymphoma and susequently transformed to dlbcl
receipt of prior chemotherapy ct or radiation therapy rt for ptcl other than a single allowed <regimen> regimen except
the patients who underwent surgery for pathologically diagnosed early breast cancer high risk stage ii or stage iii or completely resected stage iv and anticipated to undergo adjuvant chemotherapy with <regimen> regimen docetaxel doxorubicin and cyclophosphamide
in second complete remission or higher or in first remission with poor risk factors including any of the following preparative <regimen> or 2
each patient or their legally acceptable representative must sign an informed consent form icf indicating that he or she understands the purpose of and procedures required for the study and are willing to participate in the study patients eligible for autologous stem cell transplantation asct for whom r <regimen> or <regimen> is an acceptable therapy regarding the investigator s opinion measurable disease defined by at least one single node or tumor lesion 1 5 cm patients who received prior therapy with at least one but no more than two lines therapies for b cell lymphoma except for patients included in group c during the expansion part of the study
patients who are candidates for adjuvant or neoadjuvant <regimen> will meet all of the following criteria
no prior anthracycline anthracenedione based chemotherapy eg <regimen> <regimen>
recurrent disease radiosurgery including gamma knife linear accelerator based radiosurgery cyberknife and placement of <regimen> presence of any other active malignancy or prior history of malignancy except for basal cell carcinoma of the skin
in addition subjects who are unable to tolerate the 600 mg twice daily bid dose of alectinib will not be permitted to enroll unless doses of alectinib below the entry level are being investigated egdose level 1 and 2 and they have previously tolerated <regimen> at the dose being investigated
subjects enrolled on the combination therapy phase must satisfy the above inclusion criteria and also the following subjects must have inoperable locally advanced or metastatic cancer and be eligible to receive docetaxel or <regimen> cetuximab or erlotinib in combination with abt 700
however this study may be used as 2nd line treatment of patients who progressed on or were intolerant of 1st line <regimen> prior
contra indications for systemic therapy with bevacizumab avastin chemotherapy <regimen>
subject has received daratumumab or other anti cd38 therapies within 6 months before start of treatment however patients treated with <regimen> in compassionate use program or after european medicines agency ema approval and have progressive disease during daratumumab after previous response or unresponsive disease to daratumumab progressive disease after cycle 1 less than minimal response after cycle 2 or less than partial response after cycle 3 may be included in part b non secretory myeloma systemic amyloid light chain al amyloidosis or plasma cell leukemia 2 0x109 l circulating plasma cells by standard differential or
at least 3 weeks since prior chemotherapy 6 weeks for nitrosoureas and recovered no prior interstitial chemotherapy such as <regimen> implantation for present brain tumor no concurrent chemotherapy endocrine therapy at least 3 weeks since prior hormonal therapy and recovered no concurrent hormonal therapy radiotherapy see disease characteristics
ct examinations with evidence of a partial response pr or complete response cr or stable disease sd 6 months according to recist version 1 1 criteria as best response within the context of the first line treatment with <regimen> and cetuximab
must not have been treated with radiation or biological therapy prior to or after <regimen> chemotherapy
cell diffuse large cell large cell immunoblastic lymphoblastic small noncleaved cell disease has relapsed following or is resistant to primary anthracycline containing combination chemotherapy objective response to salvage <regimen> chemotherapy required ineligible for bone marrow transplantation
patients with hodgkin s disease will be eligible only if they have failed at least a <regimen> like and <regimen> like regimen
patients received 4 6 months of <regimen> or gemcitabine abraxane before sbrt was administered
systemic therapy with sorafenib or other systemic chemotherapeutic agent s less than 1 week prior to first planned <regimen>
exclusion criteria elevation of carcinoembryonic antigen cea without measurable metastatic disease medical contraindication to chemotherapy or biotherapy as <regimen> <regimen> or avastin
no prior chemotherapy and scheduled to receive <regimen> chemotherapy oxaliplatin leucovorin and 5 fluorouracil
subjects with melanoma of intraocular origin leptomeningeal metastasis or brain metastasis except as for inclusion criteria number 8 subjects taking medications which are either strong cyp inhibitors or inducers subjects with active malignancies except for wt braf stage iv and unresectable stage iii melanoma basal or squamous cell carcinoma of the skin carcinoma in situ of the cervix adequately treated stage i or ii cancer from which the subject is currently in complete remission or any other cancer from which the subject has been disease free for 5 years prior treatment with a parp inhibitor prior treatment with dacarbazine <regimen> or tmz containing regimens subjects with known allergy hypersensitivity or other contraindication to e7016 tmz or <regimen> or any of the other components of the formulations subjects with known human immunodeficiency virus infection hiv active hepatitis b or c subjects with active infections requiring specific anti infective therapy subjects who have had a major surgical procedure including tumor resection within 4 weeks prior to initiating e7016 treatment subjects scheduled for surgery during the projected course of the study chemotherapy radiation therapy or immunotherapy within 4 weeks prior to initiating e7016 treatment 6 weeks for mitomycin c or nitrosoureas or any investigational agent within 30 days prior to the first dose of study drug or who have not recovered grade 0 or 1 from any acute toxicity related to previous anticancer treatment prolongation of qt corrected the qt interval corrected for heart rate qtc interval greater than 480 ms significant cardiovascular impairment history of congestive heart failure greater than new york heart association nyha
for arm a only any other major medical illness that in the investigator s opinion would 1 prevent administration or completion of institution s standard of care <regimen> bevacizumab therapy 2 prevent administration or completion of protocol specified imaging and or 3 interfere with follow up
participants must be commencing chemotherapy with <regimen> plus bevacizumab
acceptable first line molecular targeted therapies include 1 <regimen> and sorafenib based combination 2 anti angiogenic therapy including brivanib linifanib pazopanib bevacizumab dovitinib tki258 and vargatef bibf1120
any investigational drugs within 30 days before enrollment or foreseen use of investigational agents during the study treatment with chemotherapy of any type within 12 months before enrollment patient with any type of ostomy temporary ostomy should be closed at least 6 months prior to enrollment patient who underwent total colectomy patient who had abdominal perineal resection or surgery leaving the patient without a functioning rectum any radiotherapy to the abdomen or pelvis in the 6 months prior to enrollment scheduled to receive radiotherapy to abdomen or pelvis during the study 8 a exclusion from the target population scheduled to receive any concomitant chemotherapeutic agent other than <regimen> or <regimen> agents any type of monoclonal antibodies 8
known hypersensitivity to g3139 genasense or r <regimen>
did not achieve at least a partial response to a standard salvage regimen eg rituximab ifosfamide carboplatin and etoposide phosphate <regimen> or rituximab dexamethasone cytarabine and cisplatin r <regimen>
history of allergic reactions attributed to compounds of similar chemical or biologic composition to tmz or <regimen> or azd6244
patients who have been treated with <regimen> regimen for metastatic setting may be eligible for this trial
patients who progressed despite prior therapy with <regimen> 5fu and oxaliplatin plus bevacizumab or <regimen> capecitabine and oxaliplatin plus bevacizumab
disease relapsed after refractory or failing to achieve a pr after two or more cycles of intensive salvage chemotherapy r <regimen> or other or disease relapsed after autologous stem cell transplantation
patients if enrolled should not receive live vaccine whilst receiving study treatment and for up to 30 days after the last dose of study treatment female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or180 days after the last dose of durvalumab tremelimumab combination therapy known allergy or hypersensitivity to chimeric or humanized antibodies or fusion proteins or to any of the study drugs or study drug excipients prior randomisation or treatment in a previous durvalumab and or tremelimumab clinical study regardless of treatment arm assignment any other disease metabolic dysfunction physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator makes the patient unsuitable for participation in the study
have had documented disease progression according to response evaluation criteria in solid tumors recist therasse et al 2000 within 3 months after receiving <regimen> plus bevacizumab as first line therapy for locally advanced or metastatic disease or within 6 months after receiving <regimen> with or without bevacizumab in the adjuvant setting
no prior chemotherapy one course of r <regimen> allowed
the previous treatment must have included <regimen> alone or in combination
patients who are in the opinion of their treating oncologist unable to undergo r <regimen> chemotherapy
non sterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab tremelimumab combination therapy or 90 days after receipt of the final dose of <regimen>
previously treated with <regimen> or cetuximab based combination therapy
age elder than 81 or age 61 to 80 and cirs 6 not qualifying for <regimen> therapy
submitted to <regimen> regimen according to gela s standard protocol
failed <regimen> or pentostatin cyclophosphamide rituximab pcr combination chemotherapy at any time point
patients enrolling onto arm c <regimen> or arm d mm 398 with 5 fu and leucovorin must have failed one prior line of gemcitabine based therapy with or without bbi608 in the metastatic setting
<regimen> mycophenolate mofetil mmf
anti vegf agents eg avastin may not be administered less than 4 weeks prior to <regimen> treatment
dacarbazine <regimen>
for mcrc <regimen> <regimen> bevacizumab <regimen> <regimen> bevacizumab
patient has achieved cr or partial response pr per per investigator s assessment following completion of <regimen> based therapy and has had radiological assessment within 21 days prior to randomization
prior neoadjuvant <regimen>
prior treatment with irinotecan or <regimen> is not allowed for phase ii for phase
patient is 60 years of age or older at time of randomization histologically confirmed ann arbor stage ii iii or iv dlbcl or fcl grade 3b according to the real who classification from initial diagnosis made prior to starting r <regimen> therapy results from a pre r <regimen> marrow shall be available for review
patients must have received 1 induction regimen containing anthracyclines eg <regimen> with or without rituximab or <regimen>
<regimen> or <regimen> administered at the following minimum dosages over this 12 week period
patient is eligible for the nordic <regimen> regimen
current failure of 1st line anti cancer therapy with an oxaliplatin and bevacizumab based regimen or patients relapsing within 12 months of completing adjuvant <regimen>
must be appropriate for <regimen> implant
for schedule 3 advanced metastatic tumors for which <regimen> is appropriate or advanced metastatic tumors that may be sensitive to each component of <regimen> or sensitive to topoisomerase 1 inhibitors including pancreatic colorectal esophageal gastric bladder or ovarian cancer triple negative breast cancer small cell lung cancer sclc cholangiocarcinoma among others
patient eligible for a 1st line treatment associating 5 fu irinotecan <regimen> and aflibercept
expected to receive <regimen> as adjuvant chemotherapy 4
failed at least 1 regimen containing rituximab and <regimen> cyclophosphamide doxorubicin vincristine and prednisone unless anthracyclines are contraindicated in addition to another salvage regimen unless it is determined by the treating physician that it is to the patient s best interest to receive valproic acid after the first relapse
history of stroke or transient ischemic attack within 6 months prior to day 1 of <regimen> bevacizumab initiation significant vascular disease eg aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis within 6 months prior to day 1 of <regimen> bevacizumab initiation history of hemoptysis 1 2 teaspoon of bright red blood per episode within 1 month prior to day 1 of <regimen> bevacizumab initiation evidence of bleeding diathesis or significant coagulopathy in the absence of therapeutic anticoagulation
previous receipt of any anthracycline contraindication to any of the individual components of <regimen> cyclophosphamide vincristine doxorubicin and prednisone
written informed consent histologically or cytologically confirmed adenocarcinoma of the pancreas metastatic or locally advanced disease that is considered unresectable measurable assessable disease according to recist v 1 1 documented disease progression on first line <regimen> negative pregnancy test
patients with all and cml ineligible for <regimen> conditioning
in phase 1b patients with a history of poor <regimen> tolerability as manifested by inability to tolerate standard therapeutic doses ie at minimum patients must have tolerated an oxaliplatin dose of 85 mg m2 and a 5fu dose of 2400 mg m2
history of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with <regimen>
participants in <regimen> arm including the first 21 who were enrolled in stage 1 were to be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy in the 10 days prior to beginning ipilimumab therapy
has either histologically confirmed b cell lymphomas including but not limited to diffuse large b cell lymphoma dlbcl follicular lymphoma fl primary mediastinal b cell lymphoma pmbcl marginal zone lymphoma mzl mantle cell lymphoma mcl or hodgkin lymphoma hl and has relapsed or refractory disease following at least two lines of prior standard therapy including alkylator anthracycline unless anthracycline based chemotherapy is contraindicated anti cd20 based therapy r <regimen> rituximab doxorubicin cyclophosphamide vincristine and prednisolone or dexamethasone or equivalent for non hodgkin lymphoma and must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation asct as defined by meeting at least one of the following criteria
for participants who will be receiving cyclophosphamide doxorubicin vincristine and prednisone <regimen> left ventricular ejection fraction lvef less than 50 by multiple gated acquisition muga scan or echocardiogram
the patient must meet one of the following criteria age 65 considered by the investigator to be ineligible for front line <regimen> combination chemotherapy due to reasons of
only participants whose lymphoma is untreated are allowed for the dose finding portion for the dose expansion cohort both untreated and participants who have received a maximum of one cycle of combination chemotherapy including rituximab containing regimens r cyclophosphamide doxorubicin hydrochloride vincristine sulfate prednisone <regimen> and <regimen> prior are eligible the start of previous chemotherapy cycle must occur at least 21 days prior and 28 days maximum to beginning treatment under this protocol and such cycle will count towards the maximum of 6 cycles under this study iecycle off study will count as cycle 1
candidate for systemic therapy with <regimen> <regimen> plus bevacizumab
females of childbearing potential who are sexually active with a non sterilized male partner and non sterilized male subjects who are sexually active with a female partner of childbearing potential must be willing to use 2 methods of effective contraception from time of screening through 180 days after receipt of the final dose of durvalumab tremelimumab combination therapy or 90 days after receipt of the final dose of <regimen> whichever is the longer time period
<regimen> subject is receiving only methotrexate steroids non steroidal anti inflammatory drugs nsaids and will not require washout
or if their pet scan after 2 cycles of <regimen> is positive
history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to <regimen> or hydrogel
systemic therapy includes treatments such as <regimen> chemotherapy given with or without rituximab radio immunoconjugates such as 90y ibritumomab tiuxetan and 1311 tositumomab
patients must have relapsed or progressed after r <regimen> chemotherapy or equivalent
8 cycles of <regimen> like chemotherapy as 1st line induction treatment
alkylating substances busulfan carmustine chlorambucil cisplatin cyclophosphamide dacarbazine <regimen> lomustine mechlormethamine melphalan streptozotocin tiothepa uracil mustard
eligible treatment regimens include <regimen> <regimen> 4 <regimen> 6 modified <regimen> 6 <regimen> 7 <regimen> 5fu or cp mono chemotherapy degramont regimen <regimen> <regimen>
at least 10 of each patient s malignant cells from peripheral blood lymph node skin or other extranodal sites must react with anti <regimen> as determined by immunofluorescent or immunoperoxidase staining
x 0 85 72 x serum creatinine mg dl patients with reproductive potential eg females menopausal for less than 1 year and not surgically sterilized must practice two highly effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of <regimen> or for at least 180 days after completion of durvalumab tremelimumab combination therapy
intended to receive r <regimen> every 14 or 21 days for minimum 3 cycles with rituximab planned to be given with <regimen> on day 1 or fractionated over days 1 and 21
cholangiocarcinoma for which treatment with folfox6 or <regimen> would be acceptable as determined by the investigator
those who had initiated <regimen> <regimen> but stopped oxaliplatin because of intolerable toxicity are also eligible
grade 2 according to nci common terminology criteria for adverse events version 4 0 ctcae v 4 0 known history of human immunodeficiency virus hiv infection known history of chronic hepatitis b or c patients with seizure disorder requiring medication symptomatic metastatic brain or meningeal tumors unless the patient is 6 months from definitive therapy has a negative imaging study within 4 weeks of <regimen> initiation and is clinically stable with respect to the tumor at the time of study entry
no evidence of any distant metastasis patients with microscopic peritoneal carcinomatosis detected on laparoscopy following 4 cycles on neo adjuvant <regimen> would be included
having received immuno chemotherapy r <regimen>
prior systemic therapy in the metastatic setting is allowed for as long as the therapy contained bbi608 in combination with either gemcitabine and nab paclitaxel or <regimen> toxicities
chemotherapy regimen without restriction on dose emetogenic agents must be given as part of cyclophosphamide based or carboplatin based regimen on day 0 and not at another time within the 72 hour period cyclophosphamide carboplatin or doxorubicin must be the first emetogenic agent given no cyclophosphamide doxorubicin vincristine and prednisone <regimen> regimen
pancreatic adenocarcinoma for which treatment with folfox6 <regimen> <regimen> or irinotecan would be acceptable as determined by the investigator
more than 4 months since other prior <regimen> endocrine therapy
histopathologically confirmed cd20 positive b cell non hodgkin lymphoma disease for whom r <regimen> rituximab cyclophosphamide doxorubicin vincristine and prednisone is an appropriate therapy diffuse large b cell lymphoma mantle cell lymphoma or follicular lymphoma for the expansion cohort at least 1 cohort will only include patients with newly diagnosed diffuse large b cell lymphoma
histologically confirmed diagnosis of colorectal adenocarcinoma with a phase ii or iii disease within 2 months from radical resection and intends to receive 6 months of adjuvant chemotherapy with mfolofx6 or <regimen> without adjuvant radiation indications
subjects scheduled to receive cetuximab and <regimen>
subjects in the combination therapy cohorts must meet the above inclusion criteria and be eligible to receive paclitaxel or <regimen> per most current prescribing information or at the discretion of the investigator
patients who have failed initial salvage chemotx regimens including high dose tx chemotx with stem cell support pomb ace tx <regimen> or vip must have one or more of the following check all that apply
having received r <regimen> immuno chemotherapy
inclusion in the additional population scheduled to receive at least 3 consecutive cycles of the same regimen of <regimen> or <regimen> in combination with monoclonal antibody 4
have failed adequate initial therapy lenalidomide bortezomib dexamethasone rvd thalidomide bortezomib and dexamethasone tvd or cyclophosphamide bortezomib and dexamethasone <regimen>
adriamycin bleomycin vinblastine and dacarbazine baseline <regimen> bleomycin etoposide adriamycin cyclophosphamide oncovin procarbazine and prednisone or escalated <regimen> or other induction regimens
indication for treatment with a combination including <regimen> <regimen> associated to an anti vegf drug avastin
patient who cannot receive polychemotherapy like r <regimen> r <regimen> or r <regimen> like
100 mmhg subjects with a history of hypertension must have been on stable doses of anti hypertensive drugs for 4 weeks prior to start of cycle 1 of <regimen> bevacizumab cetuximab administration uncontrolled hypertension blood pressure
no prior chemotherapy except 1 course of preinduction chemotherapy eg <regimen> cyclophosphamide doxorubicin vincristine and prednisone or a related regimen
stable metastatic pancreatic cancer after 8 12 doses of <regimen> 3
eligible for rt after r <regimen>
meeting the geriatric criteria of ineligibility for standard r <regimen> if one of the following criteria is present
known hypersensitivity reactions to temozolomide nitrosoureas or any components of the <regimen>
operative chemotherapy planned using oxaliplatin based chemotherapy regimen including <regimen> <regimen> and oxcap regimens age greater than or equal to 18 years 4
primary refractory to or in first relapse after first line therapy with r <regimen> or r <regimen>
<regimen> or immunotherapy with a checkpoint inhibitor will be considered a line of treatment
patients must be able to receive full doses of <regimen> in the opinion of the treating investigator with the exception of cisplatin
age greater than or equal to 18 years newly diagnosed all or ll receiving chemotherapy with augmented bfm <regimen> or any variant of <regimen>
for patients who are her2 positive and will be treated on the trastuzumab <regimen> cohort prior trastuzumab treatment is not allowed
the subject must have received first line therapy with rituximab cyclophosphamide hydroxydaunomycin vincristine oncovin prednisone r <regimen> or a similar standard rituximab containing front line chemoimmunotherapy regimen including but not limited to etoposide prednisone vincristine oncovin cyclophosphamide doxorubicin hydrochloride rituximab epoch r rituximab cyclophosphamide etoposide procarbazine prednisone rcepp rituximab cyclophosphamide mitoxantrone novantrone vincristine oncovin prednisone rcnop dose adjusted etoposide prednisone vincristine oncovin cyclophosphamide doxorubicin hydrocloride <regimen> and rituximab cyclophosphamide etoposide vincristine oncovin prednisone rceop
for cohort 2 disease progression during or following treatment with at least one platinum containing regimen eg gc <regimen> carbogem carboplatin paclitaxel for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence as defined by regimen is defined as patients receiving at least one cycle of a platinum containing regimen with response assessment
patients must have histologically confirmed gastrointestinal malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective or for whom <regimen> would be an appropriate therapy
reactivation of latent infection has been reported with the use of bortezomib in this population along obviously with the well recognised reactivation following r <regimen> for these patient safety reasons these patients should be excluded
patients should be monitored for supratherapeutic toxic levels of sirolimus and plx3397 as bone marrow suppression including anemia neutropenia and thrombocytopenia have been reported in patients receiving <regimen> these adverse effects may be exacerbated in combination with plx3397 for which patients will be closely monitored
known hypersensitivity reactions to temozolomide dacarbazine <regimen> hydroxychloroquine 4 aminoquinoline rapamune sirolimus rapamycin or their analogs
history of allergic reaction attributable to compounds containing boron or mannitol or any of the drugs in the <regimen> regimen
no prior treatment for metastatic disease prior neo adjuvant or adjuvant chemotherapy except <regimen> chemoradiation or radiation allowed
adjuvant <regimen> within the last 6 months is considered a line of therapy
for patients who are enrolled into the arm of <regimen> plus bevacizumab they must have metastatic colorectal cancer with predominant hepatic metastases
has previously undergone <regimen> or beam autologus sct with pbsc rescue for any stage aggressive b cell nhl including transformed indolent nhl or mantle cell lymphoma according to real classification
any history of allergy or intolerance to dacarbazine <regimen>
prior treatment with alkylating agents including tmz and <regimen>
scheduled to receive 6 cycles of standard r <regimen> rituximab cyclophosphamide doxorubicin vincristine prednisone chemotherapy as first line treatment inclusion criteria for patients in remission following chemotherapy
treatment plan to receive standard <regimen> administered either every three weeks
intent to proceed with either <regimen> consolidation or allogeneic stem cell transplantation at the discretion of the treating physician for lam 2 5
treatment with <regimen> and <regimen> is not indicated
avastin or erbitux 1 cycle defined as 2 doses of <regimen>
a histologically confirmed solid tumor of the gastrointestinal tract including advanced unresectable metastatic or recurrent colorectal carcinoma crc for which treatment with folfox6 with or without bevacizumab <regimen> with or without bevacizumab <regimen> or regorafenib would be acceptable as determined by the investigator
patients enrolled at the dana farber cancer institute must be receiving <regimen> chemotherapy to be eligible since they will be enrolled in the pharmacokinetics sub study
all patients must have a histologic or cytological diagnosis of de novo dlbcl and be scheduled to receive first line chemotherapy with r <regimen> given every 21 days r <regimen> 21 within 6 weeks of their enrollment and for 6 cycles
no prior systemic chemotherapy for metastatic disease subjects who received adjuvant therapy with <regimen> and at the time of recurrence are at least 6 months away from last chemotherapy are eligible for this study
hepatocellular carcinoma for which treatment with folfox6 or <regimen> would be acceptable as determined by the investigator
smoldering or chronic stage <regimen> expressing adult t cell leukemia defined by the shimomyama criteria 37 are eligible
dexamethasone high dose cytarabine and cisplatin <regimen> etoposide methylprednisolone high dose cytarabine and cisplatin
no more than 2 prior chemotherapies including f fc <regimen> b br therapy
mean qt interval corrected for heart rate qtc 470 ms calculated from 3 electrocardiograms ecgs using frediricia s correction current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses which are not to exceed 10 mg day of prednisone or an equivalent corticosteroid any history of hypersensitivity to durvalumab or tremelimumab <regimen> or their excipients any unresolved toxicity ctcae grade 1 from previous anti cancer therapy
the patients treated by other anti cancer treatment except <regimen> regimen or r rituximab <regimen> regimen at 21 days interval
previous antineoplastic treatment other than the 6 cycles of <regimen> for the initial treatment of dlbcl
patients must have received <regimen> at 250 mg bid on a continuous dosing schedule for at least 90 days patients must be planning to start treatment at least three days but no more than 30 days after discontinuing <regimen> patients who were not able to tolerate 250 mg bid of crizotinib are not eligible for this study
donor evaluation and collection procedure as per <regimen> standard operating procedures sop
have a plan by treating physician to receive <regimen> or <regimen> avastin
known allergic reactions against any component of <regimen> regimen
cyclophosphamide doxorubicin vincristine and prednisone <regimen>
failure is defined as radiologic progression eligible for <regimen> measurable disease according to recist v1 1 main
patient is scheduled to receive treatment with carboplatin or <regimen> or combination where one of the drugs is a platinum
patients must be appropriate candidates for at least 2 cycles of <regimen> or avd this could include patients ranging from favorable risk early stage disease to poor prognosis advanced stage disease
history of malignancy other than multiple myeloma within 5 years before the first dose of <regimen> exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix or breast or other non invasive lesion that in the opinion of the investigator with concurrence with the sponsor s medical monitor is considered cured with minimal risk of recurrence within 5 years
treated with at least one <regimen> or <regimen> derived doxorubicin containing regimen
prior treatment with any cytotoxic chemotherapy including but not limited to temozolomide lomustine nimustine hydrochloride acnu bis chloroethyl nitrosourea bcnu procarbazine vincristine carboplatin irinotecan <regimen> cyclophosphamide etoposide etc
at least 30 of malignant cells reactive with anti <regimen> as determined by immunofluorescence studies
eligibility for dose escalation cohort histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective or solid tumor for which <regimen> is considered standard
biopsy at hl relapse or when refractoriness disease is diagnosed must be done prior to bv <regimen> if
patients with unresected metastases from colorectal cancer patients may be either untreated with chemotherapy or currently receiving first line 5 fu based chemotherapy folinic acid fluorouracil irinotecan hydrochloride <regimen> capecitabine irinotecan hydrochloride <regimen> fluorouracil leucovorin calcium oxaliplatin <regimen> or capecitabine oxaliplatin <regimen> with or without bevacizumab within 10 months of beginning adapt therapy with at least stable disease radiographically patients who received prior adjuvant chemotherapy with 5 fu capecitabine or <regimen> are eligible if adjuvant therapy was completed greater than 6 months ago
systemic chemotherapy indication compatible with the <regimen> bevacizumab combination
if subject received prior therapy with irinotecan they will be eligible to receive the <regimen> regimen
neo adjuvant treatment with docetaxel doxorubicin and cyclophosphamide <regimen> completed one year before inclusion
fp xp ts 1 cisplatin <regimen>
radiotherapy before <regimen> induction regimen
female breast cancer patients receiving adjuvant <regimen> chemotherapy
patient has known allergy or hypersensitivity to <regimen> 101 doxorubicin epirubicin other anthracyclines anthracenediones or any of the components used in the study drug formulations
patients must be registered within 28 days of documented disease progression on first line chemotherapy with bevacizumab plus either <regimen> <regimen> or <regimen> this progression must have occurred within 90 days after the last dose of bevacizumab patients who discontinued oxaliplatin continued with 5 fu lv or capecitabine and bevacizumab and then had subsequent progression while on fluoropyrimidine and bevacizumab are eligible patients who discontinued bevacizumab due to adverse events in the first line setting are not eligible
<regimen> irinotecan hydrochloride fluorouracil leucovorin calcium
exclusion criteria history of severe and uncontrolled allergic reactions to bevacizumab prior treatment with <regimen> or bevacizumab within the preceding 4 weeks patients currently receiving or have received anticancer therapies within 4 weeks of the start of study treatment including chemotherapy radiation therapy antibody based therapy etc
female patients who are pregnant or breastfeeding or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
participants who have had chemotherapy other than <regimen> or r <regimen> or radiotherapy other than palliative radiation for medical emergencies like cord compression within the last 4 weeks
prior <regimen> xp <regimen> or sp s 1 cisplatin treatment could be eligible but prior taxane are ineligible
receiving cyclosporine csa or tacrolimus <regimen> since the first month post transplant
patients must have relapsed after high dose therapy and autologous transplantation or be ineligible for high dose therapy and autologous transplantation patients that have failed autologous transplantation are those with persistent disease 30 days after transplant those ineligible for autologous transplant include those with chemoresistant disease ie patients who have not achieved a partial response or better with their most recent chemotherapy regimen are expected to have a poor outcome from autologous transplant eg dlbcl relapsing within one year of rituximab cyclophosphamide doxorubicin hydrochloride vincristine sulfate prednisone r <regimen> like chemotherapy double hit lymphoma v myc myelocytomatosis viral oncogene homolog avian positive myc lymphoma persistent positron emission tomography pet positivity after chemotherapy are unable to collect sufficient or tumor free autologous stem cells per seattle cancer care alliance scca standard practice are unable to tolerate the high dose autologous conditioning regimens or who refuse a high dose autologous transplant regimen
receiving adjuvant chemotherapy with <regimen> 5 fu leucovorin oxaliplatin regimen
primary invasive breast carcinoma with lymph node positive with curative surgery with <regimen> chemotherapy
documented refractoriness to an <regimen> regimen
patients with early breast cancer planned to receive 3 weekly or dose dense anthracycline cyclophosphamide combination or 3 weekly taxane containing chemotherapy regimen or patients with nhl planned to receive r <regimen> 14 or r <regimen> 21 immunochemotherapy as 1st line treatment with the indication for g csf prophylaxis with pegfilgrastim for the prevention of fn and reduction in cin duration
patients who are not transplant eligible or who did not respond to chemotherapy may be considered for the study following a single regimen of chemotherapy such as r <regimen> or <regimen> there
stage iii and iv disease with failure on mechlorethamine vincristine procarbazine and prednisone <regimen> like regimen alternative noncross resistant regimen eg doxorubicin bleomycin vinblastine and dacarbazine <regimen> or a combination eg <regimen> abv
ecog performance status 2 myelosuppressive chemotherapy naive scheduled to receive and anticipated to complete the following chemotherapy <regimen>
progressive disease within 9 months after prior first line chemotherapy platinum based chemotherapy or stz tem <regimen> based chemotherapy in net g3
this does not include patients who have initiated r <regimen> at an outside institution within 2 weeks of enrollment
patients suitable for intensive treatment eg hyperfractionated cyclophosphamide vincristine doxorubicin hydrochloride and dexamethasone with high dose methotrexate and cytarabine <regimen>
cd20 positive diffuse large b cell lymphoma lbcl of any stage including subtypes mediastinal large b cell centroblastic immunoblastic t cell rich b cell and anaplastic b cell lymphoma who will receive standard r <regimen> as first line chemotherapy will be included
patients with indolent nhl must be relapsed or refractory to at least one prior line of therapy <regimen> cvp chlorambucil or fludaribine prior treatment with rituximab is required
one prior line of therapy defined as either one non transplant regimen such as <regimen> <regimen> or <regimen> one autologous stem cell transplant or one regimen of non transplant induction therapy followed by a single autologous stem cell transplant without hematologic progression between induction and autologous stem cell transplant asct
continuous 5 fu containing regimens such as folfox6 and <regimen> are allowed as both the 5 fu bolus as well as the oxaliplatin and irinotecan administration is completed on day 1 of chemotherapy
complete or partial remission for at least 3 months after completion of prior <regimen> <regimen> <regimen> abv <regimen> <regimen> abv <regimen> <regimen> or other polychemotherapy regimen with or withou
other tumour types than colon adenocarcinomas current severe neutropenia leucopenia or thrombocytopenia severely reduced liver or renal function unresolved bowel obstruction or sub obstruction uncontrolled crohn s disease or ulcerative colitis current chronic diarrhoea contraindication for corticosteroid administration history of prior serious allergic or pseudo allergic reaction any other serious illness or medical condition symptomatic peripheral neuropathy grade 2 received mangafodipir 5 weeks before planned start of chemotherapy received any of the <regimen> drugs 5 weeks before planned start of chemotherapy any plans of administered other anti cancer therapy including radiotherapy concurrent with this study fertile females males with reproductive potential not implementing adequate contraception measures phaeochromocytoma
eligible subjects must have completed appropriate treatment for their primary disease and be off cytotoxic chemotherapy and corticosteroids for at least 1 month prior to enrollment patients with stage iii iv breast cancer who have completed chemotherapy and are continued on <regimen> are eligible hormonal and bisphosphanate therapies are allowed
prior treatment with <regimen> is allowed if it has been at least 3 months from placement
patients who received no prior adjuvant therapy must have received 2 prior chemotherapy regimens for metastatic disease eg <regimen> followed by <regimen>
first line palliative treatment with cytotoxic agents will be started <regimen> <regimen> capecitabine paclitaxel or docetaxel
all stages of <regimen> expressing adult t cell leukemia except smoldering are eligible patients with chronic lymphoma or acute acute t cell leukemia lymphoma atl are eligible
planned to start docetaxel component of fec d or ac d or first cycle of dose dense ac t tc fec d or <regimen> chemotherapy
patients receiving non myeloablative conditioning are not allowed on the observational arm reduced toxicity conditioning with <regimen> thio is allowed on the observational arm
the subject is pregnant or breast feeding the subject intends to undergo treatment with the <regimen> at the time of this surgery or has received the <regimen> 30 days from w1d1 surgery
pregnant or breastfeeding women or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen>
known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of <regimen>
pre phase therapy with prednisolone and or vincristine for one week duration prior to commencement of cycle 1 of r <regimen> is permissible
patients who are feasible for treatment with <regimen> prior adjuvant or palliative treatment is allowed
group a post induction therapy patients who have received only one prior treatment regimen eg vad <regimen> blt d mp bird or dvd with at least 20 patients having received a revlimid based regimen or group b 1st line of therapy patients with relapsed refractory multiple myeloma who have received two or more prior treatment regimens
have recurred or progressed within 6 months of the last cycle of <regimen>
lymphoma patients receiving ice ifosfamide carboplatin etoposide <regimen> dose adjusted rituximab etoposide prednisone vincristine cyclophosphamide doxorubicin and other inpatient lymphoma regimens
ugt1a1 genotype other than 1 1 1 28 or 28 28 known dihydropyrimidine dehydrogenase dpd deficiency prior treatment with irinotecan and or bevacizumab unable or unwilling to discontinue and substitute if necessary use of prohibited drugs for at least 14 days fruits and juices for at least 7 days prior to day 1 of <regimen> bevacizumab initiation see section 11 2
and or bcr abl positive includes patients initiated on first course of <regimen> before cytogenetics known
for patients enrolling onto arm b <regimen> or arm c <regimen> known hypersensitivity to 5 fluorouracil leucovorin known dihydropyrimidine dehydrogenase dpd deficiency known hypersensitivity to oxaliplatin or other platinum containing compounds known hypersensitivity to irinotecan uncontrolled seizure disorder active neurological disease or known cns disease
previously treated by low dose <regimen> for active disease requiring treatment per iwcll criteria
chemotherapy 6 cycles of <regimen>
subject treated by chemotherapy induced ovarian failure including alkylant agents except less than 8 <regimen>
this includes 3 6 cycles of <regimen> cyclophosphamide doxorubicin vincristine prednisone or an equivalent <regimen> like regimen
patients with a known sensitivity to olaparib or its components module 1 or components of <regimen> module 2
first line treatment 6 cycles of r <regimen> 2x r or 6 cycles of <regimen> r 2xr
subjects must have received at least 3 cycles of <regimen> like or any anthracycline base chemotherapy or at least 2 full cycles of <regimen> like chemotherapy
no polifeprosan 20 with carmustine implant <regimen> at the time of prior surgery for gbm
have been used <regimen> as an adjuvant therapy
ac doxorubicin and vinorelbine or <regimen> in the presence of 1 patient risk factor 65 yrs extensive bone marrow involvement or prior extensive radiotherapy on bone tissue
known hypersensitivity to any of the treatment components of modified folfox6 <regimen> oxaliplatin 5 fu and leucovorin or ramucirumab dp
de novo diffuse large b cell lymphoma that fails to achieve a pet negative complete response to primary rituximab and anthracycline based multi agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double triple hit features defined by overexpression by standard immunohistochemistry of c myc plus bcl2 and or bcl6 or presence of chromosomal translocations as detected by break apart fish involving igh myc plus igh bcl2 and or igh bcl6 and who only received standard chemoimmunotherapy with rituximab cyclophosphamide vincristine and prednisone r <regimen> for induction and present at least stable disease after consolidation or salvage chemotherapy
are itraconazole and fluconazole for treatment or prevention of fungal infection hydrocortisone and dexamethasone for treatment of nausea vomiting fluid retention and methylprednisolone as a part of the <regimen> regimen
all subjects unsuitable for chemoimmunotherapy with <regimen> in the opinion of the investigator
prior cytotoxic chemotherapy for metastatic disease except prior gemcitabine or <regimen> 5fu leucovorin irinotecan oxaliplatin
non sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab tremelimumab combination therapy or 90 days after receipt of the final dose of <regimen> not engaging in sexual activity is an acceptable practice however occasional abstinence the rhythm method and the withdrawal method are not acceptable methods of contraception male patients should refrain from sperm donation throughout this period
<regimen> cytoxan novantrone oncovin vincristine etoposide prednisone chemotherapy are not eligible for inclusion in this study
anti cancer chemotherapy or biologic therapy within the lesser of i 21 days or ii the usual cycle length of the regimen eg14 days for <regimen> prior to the first planned dose of bbi608 placebo
at least one measurable or evaluable lesion in the first line chemotherapy 5 fu based regimen ecf eof eox <regimen> <regimen> with the efficacy evaluation of non pd
treatment with <regimen> within 3 months or rituximab combination therapies eg with bendamustine fludarabine ibrutinib or cytotoxic drugs within 6 months prior to enrollment
subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive docetaxel or <regimen> cetuximab or erlotinib per most current prescribing information or at the discretion of the investigator
patients scheduled to receive the first line first cycle <regimen> 5 fu oxaliplatin leucovorin or <regimen> 5 fu irinotecan leucovorin
polychemotherapy type <regimen> <regimen> <regimen> associated or not with targeted therapies adapted to the expression of braf and ras whatever the route of administration of the proposed oral or intravenous therapies
greater than 400 il2ra sites per malignant cell by radiolabeled anti <regimen> binding
in the case of de novo diffuse large b cell lymphoma prior treatment must include r <regimen> or r <regimen> like therapy as well as second line autologous stem cell transplantation unless the patient is not eligible
the patient must have completed at least 4 months of adjuvant chemotherapy ie <regimen> <regimen> or other such as 5 fluorouracil leucovorin oxaliplatin <regimen> 5 fluorouracil leucovorin 5fu lv capecitabine
male patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens f fc fr <regimen> or alkylator chlorambucil bendamustine based regimens
only dose reductions for vincristine are allowed during r <regimen> central nervous system prophylaxis by intrathecal therapy is allowed
prior chemotherapy with combination of capecitabine or 5 flourouracil 5 fu and temozolomide or dacarbazine <regimen> will be excluded patients can have had prior therapies up to 3 prior chemotherapy regimens such as streptozocin anthracyclines irinotecan etoposide or a platinum agent including single agent capecitabine or 5fu or temozolomide or <regimen>
have received at least one treatment of either <regimen> or gemcitabine abraxane based regimens in both neoadjuvant and adjuvant setting
in pr or cr after 1 2 other salvage chemotherapy regimens eg 3 courses of dexamethasone high dose cytarabine and cisplatin <regimen> 2 courses of cyclophosphamide mechlorethamine vincristine procarbazine and prednisone <regimen>
history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide vorinostat dacarbazine <regimen> dome dic imidazole carboxamide
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
documented objective response or stable disease lasting for 6 months or more to last prior anti egfr cetuximab or panitumumab in combination with irinotecan or <regimen>
previously untreated all burkitt s lymphoma or lymphoblastic leukemia receiving induction chemotherapy with <regimen> or variants of the <regimen> regimen
patient for whom a decision of treatment with <regimen> has been taken in the frame of its marketing authorization
newly diagnosed stage iii iv dlbcl considered poor candidates for r <regimen>
newly initiated with <regimen> as their first line therapy for previously untreated advanced melanoma between june 2015 and june 2016
will receive neoadjuvant treatment using <regimen> or chemoradiotherapy
women of child bearing potential and men with female partners of child bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child a while receiving treatment of guadecitabine decitabine or azacitidine and for at least 3 months after completing treatment and b while receiving treatment with high intensity tc or <regimen> and for at least 6 months after completing treatment
treatment by <regimen> or <regimen> not indicated
failure to achieve initial complete remission with <regimen> and or <regimen> and crossover or hybrid therapy
more than 2 years since prior chemotherapy rituximab combination therapy eg <regimen> rituximab or cyclophosphamide vincristine and prednisone cvp rituximab
patients cannot have had a second line salvage treatment chemotherapy biologic agents investigational drugs or radiation or have had an autologous or allogeneic hematopoietic stem cell transplantation patients can have had mixed frontline therapy such as 2 4 cycles of <regimen> doxorubicin bleomycin vinblastine and dacarbazine followed by 2 4 cycles of bleomycin etoposide doxorubicin cyclophosphamide vincristine procarbazine and prednisone <regimen> as long as the induction chemotherapy is not more than 8 cycles in total length
to be treated with adjuvant <regimen> chemotherapy
participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received 1 of the following for their metastatic disease <regimen> nanoparticle albumin bound paclitaxel gemcitabine ts 1
no previous treatment with dacarbazine <regimen> or tmz containing regimens for the phase 2 cohort 4 mtnbc only histologically confirmed metastatic triple negative breast cancer
methotrexate etoposide ifosfamide <regimen> regimen for patients 25 years doxorubicin cisplatin ifosfamide api ai regimen for patients 26 50 years
eligible for postoperative adjuvant <regimen> chemotherapy
known hypersensitivity reactions to temozolomide nitrosoureas or any other components of the <regimen>
participants will be eligible to enter the rollover study when the parent study is closed or planned to be closed and the participant is on <regimen> or on a drug combination with another medication established while in his her parent study and in the opinion of the investigator and confirmed by the millennium medical monitor the participant may continue to benefit from treatment with ixazomib eg response to therapy or stable disease without evidence of disease progression
patients who achieve only a partial response to <regimen> as initial therapy will be eligible
breast milk cannot be stored for future use while the mother is being treated on study or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy
because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with <regimen> breastfeeding must be discontinued for eligibility
patients must have progressed on one or more prior chemotherapy treatment regimens including at least one trial of a 5 fu oxaliplatin based therapy <regimen> in combination with bevacizumab
for patients receiving r <regimen> <regimen> may be administered starting on day 2 at the discretion of the treating physician age
exclusion criteria radiosurgery including gamma knife linear accelerator based radiosurgery cyberknife and placement of <regimen> presence of any other active malignancy or prior history of malignancy except for basal cell carcinoma of the skin cervical carcinoma in situ early stage prostate carcinoma not requiring active treatment new york heart association
performance score of at least 60 by karnofsky adequate major organ system function as demonstrated by left ventricular ejection fraction of at least 40 myeloablative <regimen> reduced intensity regimen 3 left ventricular ejection fraction of at least 30 nonmyeloablative regimen 2
disease progression or relapse after first line <regimen> treatment or <regimen> and radiotherapy combination treatment
preferred patients are those who have progressed on first line <regimen> or <regimen> with or without bevacizumab
treated with <regimen> or r <regimen> on ecog e4494
scheduled to receive r <regimen> chemotherapy
in part i subjects still have to undergo at least 1 planned cycle with <regimen>
gemzar tarceva and 5 fu or xeloda oxaliplatin taxotere and <regimen> are permitted
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ two highly effective birth control methods from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy
other <regimen> variants substitution allowed for 1 component with a drug of the same mechanism of action
all patients accept 6 cycles <regimen> chemotherapy regimen
no prior systemic chemotherapy including polifeprosan 20 with carmustine implant <regimen> for the current gbm
1 all patients must be refractory to or not eligible for available therapies expected to provide clinical benefit with the exception that if a patient would meet national comprehensive cancer center network nccn guidelines for consideration of treatment with <regimen> then that patient can be enrolled to this trial as this is a combination trial of brentuximab vedotin plus tak228
persistent lymphoma and stable disease after at least 2 cycles of <regimen> like or any anthracycline base chemotherapy or at least 1 full cycle of <regimen> like chemotherapy part a and b
<regimen> fr pcr br etc 3 fludarabine refractory understand and voluntarily sign an informed consent form able to adhere to the study visit schedule and other protocol requirements
history of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or <regimen>
germinal center b cell diffuse large b cell lymphoma gcb dlbcl relapsed or refractory to at least one prior regimen eg rituximab cyclophosphamide doxorubicin vincristine prednisone r <regimen> and not a candidate for standard salvage regimens or autologous or allogeneic stem cell transplant
at least 4 weeks since prior chemotherapy 6 weeks for nitrosoureas or mitomycin including <regimen> therapy and recovered endocrine therapy
vincristine ifosfamide doxorubicin etoposide <regimen> with concomitant sodium 2 mercaptoethane sulfonate mesna according to local standards
exclusion criteria patients who had received chemotherapy other than r <regimen> or <regimen> after diagnosis 2
no more than 1 pretreatment before second line therapy with chlorambucil or f fc <regimen> b
have a history of hypersensitivity to dacarbazine <regimen>
inclusion criteria women with diagnosis of breast cancer undergoing adjuvant neoadjuvant chemotherapy with either fec fac <regimen> or ec docetaxel combinations 3 18 years of age performance status 0 2 ability to provide written informed consent
obtain no partial response after first line chemotherapy including anthracyclines rituximab r <regimen> <regimen> <regimen> or the like or else
eligible for r <regimen> or r coep based therapy
only patients must have histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard therapy would include <regimen> or for which standard curative or palliative measures do not exist or are no longer effective
men or women 18 years old at the time of signing the icf patients with histologically proven colorectal adenocarcinoma with potentially resectable liver metastases no previous chemotherapy for metastatic crc the patient is due to receive first line metastatic chemotherapy regimen with <regimen> as a neoadjuvant the patient must have an ecog performance status 0 or 1 the patient must have sufficient bone marrow reserve hepatic and renal functions detailed disease specific criteria exist and can be discussed with contacts listed below
history of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib or other agents r <regimen> used in this study
placement of <regimen> in the resection cavity significant amount of hemorrhage within the resection cavity seen on immediate post operative scan 4
primary refractory disease as defined by progression while receiving or within 6 months of completion of a chemoimmunotherapy regimen such as fludarabine cyclophosphamide and rituximab <regimen> or pentostatin cyclophosphamide and rituximab pcr
patients with significant renal cr greater than 1 5 mg dl or creatinine less than 40 cc min or hepatic bilirubin greater than 2 5 u dysfunction not due to tumor involvement will not be eligible to receive <regimen> r chemotherapy
bevacizumab or <regimen> which includes chemotherapy prior to and post hepatic resection
patients who are refractory to standard therapy patients with metastatic irinotecan refractory colon cancer or recurrent metastatic head and neck cancer may enroll as <regimen> is among the standard options for such patients patients with locally advanced treatment nave head and neck cancer who are candidates for radiation with cetuximab are not eligible as radiation provides them a survival benefit and the number of projected cetuximab doses would be only seven
women of child bearing potential must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and for 5 months 150 days after the last dose of atezolizumab 6 months after the last dose of bevacizumab and 6 months after the last dose of <regimen> men with female partners of child bearing potential must agree to use adequate contraception prior to the study for the duration of study participation and for 6 months after the last dose of bevacizumab and 6 months after the last dose of <regimen>
patients in remission following <regimen> induction therapy who are receiving consolidation treatment
non sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 180 days after receipt of the final dose of durvalumab tremelimumab combination therapy or 90 days after receipt of the final dose of <regimen>
gross total resection partial resection gbm surgery placement of <regimen>
subjects who initiate carfilzomib treatment on a combination regimen subsequently discontinue all concomitant medications but remain on <regimen> in later cycles remain eligible for participation in the study
exception administration on short time of glucocorticoids 7 days one administration of vincristine or cyclophosphamide one cycle of <regimen> urgent administration of the another cytostatics
no prior therapy with mustargen oncovin procarbazine prednisone <regimen>
confirmed malignancy scheduled to receive <regimen> or carboplatin in combination with agents of minimal low or moderate emetic potential
known hypersensitivity to any temozolomide component or to dacarbazine <regimen>
for lapc or mpc <regimen> gemcitabine or gemcitabine nab paclitaxel
scheduled to receive 6 months of oxaliplatin based adjuvant chemotherapy at a dose of 85 mg m of oxaliplatin every 2 weeks simplified <regimen> 4 regimen
verification of bone marrow status must be performed at the time of response evaluation following <regimen> chemotherapy and within 56 days of study enrollment
eligible for 5fu lv or <regimen> chemotherapy
cohort 3 received prior tmz or <regimen> mutant or wild type gnaq gna11 status
conversion criteria c2 assessed prior to conversion to evr based is regimen evr cannot be initiated prior to 30 days after liver transplantation subjects with any of the following will remain on <regimen> based is regimen
at least 3 months since prior polifeprosan 20 with carmustine implant <regimen> endocrine therapy
female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol <regimen> regimen or male subject diagnosed with metastatic castration resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol prodoc regimen
subjects must be planned to receive full course 6 cycles of <regimen> chemoimmunotherapy as per clinical standard of care patients may have de novo dlbcl and or any of the following
not received previous therapy for metastatic colorectal disease but for whom <regimen> treatment is clinically indicated
history of allergic reaction attributed to compounds of similar chemical or biologic composition to gleevec or any component of the <regimen> regimen
suitable to receive <regimen> regimen as first line metastatic treatment
clinically significant ascites any anti tumor treatment except <regimen> as the first line therapy for pancreatic adenocarcinoma before enrollment
the patient is enrolled in an interventional clinical trial in which treatment for cns tumor s is managed through a protocol that excludes <regimen> treatment
all subjects must have a confirmed diagnosis of malignancy and receiving highly emetogenic chemotherapy first time vac <regimen> and cddp doxorubicin
for patients randomized to carboplatin alone who decide to crossover to <regimen> at time of progression a mandatory biopsy will be required if tumor is safely accessible prior to initiating nivolumab participants must also agree to undergo this biopsy if applicable
<regimen> or 2 before surgery would be medically inappropriate tumor of the oropharynx tumor involvement of the following sites or any of these signs or symptoms likely to be associated with t4b
subjects previously treated with <regimen> or tmz
fdg pet positivity after two cycles of <regimen> treatment 5
or <regimen>
at least 6 months since prior polifeprosan 20 with carmustine implant <regimen>
a prephase to reduce tumor burden prior to start of r <regimen> is allowed
unfit for full dose <regimen> chemotherapy
scheduled for treatment with first line chemotherapy either <regimen> b <regimen> b or capecitabine b
patients must have failed relapsed or refractory front line standard anthracycline containing regimen such as <regimen> <regimen> or <regimen>
must have either 1 failed to meet national cancer institute nci working group criteria for complete or partial response after therapy with a regimen containing fludarabine phosphate flu or another nucleoside analog eg2 chlorodeoxyadenosine 2 cda pentostatin or experience disease relapse within 12 months after completing therapy with a regimen containing flu or another nucleoside analog 2 failed flu cyclophosphamide cy rituximab <regimen> combination chemotherapy at any time point or 3 have 17p deletion cytogenetic abnormality patients should have received induction chemotherapy but could be transplanted in 1st cr 4 patients with a diagnosis of cll or small lymphocytic lymphoma or a diagnosis of cll that progresses to prolymphocytic leukemia pll or t cell cll or pll
patients planned to be treated with r <regimen> 14 ie
first relapse from a complete response or complete response unconfirmed after a front line chemotherapy regimen eg <regimen> like regimen
patients who had received anthracycline based therapy such as <regimen> or <regimen> like regimens as the initial treatment
plan for treatment with frontline multi agent anthracycline containing chemotherapy for curative intent for example <regimen> <regimen> epoch a frontline therapy program can include different sequential phases of treatment including high dose therapy and autologous stem cell transplantation
90 g l total bilirubin 2 x upper limit of normal 1 5 x uln for <regimen> ast sgot and alt sgpt
treatment with corticosteroids csa or <regimen>
no prior mechlorethamine vincristine procarbazine and prednisone <regimen>
the mtd for <regimen> in patients with hepatocellular cancer was found to be 600 mg daily therefore enrollment for these patients will be limited to pazopanib dose levels at or below 600 mg
or clinical evidence of cns metastases exceptions are subjects who have completed local therapy and who meet both of the following criteria i are asymptomatic and ii have no requirement for steroids 6 weeks prior to start of <regimen> treatment
cyclophosphamide and doxorubicin ac taxotere doxorubicin and cyclophosphamide <regimen> taxotere and cyclophosphamide tc or taxotere carboplatin and trastuzamab tch prior to registration
dlbcl patients who are not suitable for receiving r <regimen> chemotherapy or plan to receive other chemotherapy
no prior chemotherapy for lymphoma except for a single course of <regimen> <regimen> r
contraindication to any of the components of the <regimen> chemotherapy regimen as per investigators judgement
completion of at least 3 months but no more than 6 months of standard induction chemotherapy for lapc which may include <regimen> or gemcitabine and nab paclitaxel preferably within 2 4 weeks but no longer than 8 weeks
female patients with reproductive potential eg females menopausal for less than 1 year and not surgically sterilized must agree to practice two highly effective contraceptive measures for the duration of study drug therapy and for at least 90 days after completion of <regimen> or for at least 180 days after completion of durvalumab tremelimumab combination therapy
at a minimum such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine eg <regimen> and <regimen> or their variants
female patients of childbearing potential ie not surgically sterile or post menopausal who are sexually active with a non sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen>
patients must have received a front line standard anthracycline containing regimen such as <regimen> <regimen> or <regimen>
patients receiving bv plus <regimen> as first line treatment
cohort 1 no prior tmz or <regimen> mutant
fludarabine phosphate cyclophosphamide and rituximab <regimen>
entry criteria specific for dose escalation phase part a subjects with cd20 positive histologically or cytologically confirmed diffuse large b cell lymphoma dlbcl including transformed low grade lymphoma who have relapsed or refractory disease following at least two prior standard treatment regimens eg r <regimen> or similar first lineregimen and at least one second line salvage regimen and or autologous stem cell transplant asct in chemotherapy sensitive patients with the following
patient must have a medical oncology consult and be recommended to receive one of the following regimens cyclophosphamide and doxorubicin ac taxotere doxorubicin and cyclophosphamide <regimen> taxotere and cyclophosphamide tc or taxotere carboplatin and trastuzumab tch prior to registration
if mcrc they should have received at least one regimen of 5 fluouracil based systemic chemotherapy such as <regimen> <regimen> <regimen> or <regimen> with or without a vegf or egfr receptor inhibitor
patients with relapsed or refractory diffuse large b cell lymphoma who have previously received r <regimen> or equivalent chemo immunotherapy and high dose chemotherapy with stem cell rescue or who are ineligible for high dose therapy with stem cell rescue
patients with advanced incurable solid malignancy who are likely to benefit from <regimen>
methotrexate mtx high dose cytarabine <regimen> cyclophosphamide vincristine doxorubicin and dexamethasone <regimen> bortezomib thalidomide dexamethasone and 4 day continuous infusions of cisplatin doxorubicin cyclophosphamide and etoposide <regimen>
patients with a history of severe hypersensitivity reaction to capecitabine 5 fu temozolomide or <regimen> will be excluded ieanaphylaxis or anaphylactoid reactions
hypersensitivity to dacarbazine <regimen>
patients are eligible for this trial if during the previous <regimen> administration they underwent one dose reduction of oxaliplatin due to sensory neuropathy provided the neuropathy has now resolved to grade 1 or less
patients with de novo refractory disease progression of disease as best response at 1st line therapy with <regimen> avastin
all subjects must personally sign and date the consent form before initiating any study specific procedures or activities all subjects must be able to comply with all the scheduled procedures in the study histologically or cytologically confirmed cd19 positive non hodgkin lymphoma chemotherapy refractory disease defined as one or more of the following relapsed in 6 months after most recent therapy progressive disease in the standard r <regimen> or <regimen> chemotherapy disease progression or relapsed in 12 months of asct must have biopsy proven recurrence in relapsed subjects if salvage therapy is given post asct the subject must have had no response to or relapsed after the last line of therapy
induction <regimen> up to 4 cycles
subjects in cohorts 6 and 7 must have received <regimen> immediately prior to study entry but must not have received that ipilimumab as part of a clinical trial
major surgical procedure open biopsy or significant traumatic injury within 28 days before start of day 1 of treatment with <regimen> radiotherapy within 4 weeks prior to first dose of <regimen> active cardiac disease including any of the following
patients who are scheduled to receive rituxan or any other therapy eg xrt radioimmunotherapy as adjuvant therapy after completion of r <regimen> 21
patients who were treated with 5fu and leucovorin in the adjuvant setting or with 5fu and leucovorin lv or and <regimen> regimen for metastatic setting may be eligible for this trial
patients who are scheduled to start <regimen> based on the atezolizumab package insert and the optimal use promotion guideline
measurable disease on cross section imaging that is at least 1 5 cm in the longest diameter and measurable in two perpendicular dimensions appropriate candidate for systemic immune chemotherapy such as the standard <regimen> 6 cycles as determined by the treating physician age
refractory disease after at least 2 courses of anthracycline based immune chemotherapy eg r <regimen> and patient is not eligible for intensive salvage regimens including hdt with asct
be scheduled to receive <regimen> regimen as adjuvant therapy subjects who meet the conditions at screening test as follows
hiv positive or infectious hepatitis type a b or c candidates eligible for intensive rescue therapies ex r <regimen> plus alemtuzumab allogenic transplant
serum total bilirubin 2 0 mg dl 34 mol l except in patients with hemolytic anemia or with gilbert syndrome calculated creatinine clearance of 50 ml min for patients who will have dhaox chemotherapy or 70 ml min for patients who will have <regimen> chemotherapy
inclusion criteria patients with cyto histological diagnosis of stomach adenocarcinoma and gastric esophageal junction in stages iii and iv which are tributaries of the <regimen> chemotherapy scheme
prior treatment with <regimen> as first line treatment to which the patient is deemed resistant or intolerant
<regimen> regimen as adjuvant therapy 4
secondary resectable hepatic metastasis converted by <regimen> 4 regimen 2
18 70 years old sex is not restricted pathologically diagnosed as gastric adenocarcinoma or gastroesophageal junction adenocarcinoma did not receive neoadjuvant chemotherapy or radiotherapy before surgery received the 2 3 cycles of chemotherapy of <regimen> regimens or 1 2 cycles of <regimen> or sox regimens after operation
participants must have never received previous r <regimen> treatment
previous <regimen> treatment for patients who will be included in the <regimen> cohort
history of anaphylactic reaction or known intolerance to atropine sulfate or to loperamide or to antiemetics administered in association with <regimen>
are under <regimen> for treatment of colon or breast cancer at a regimen of 2 weeks on and 1 week off 14 7 and a daily doses between 2000 and 2500 mg m2
progression following at least twelve weeks of treatment with single agent erlotinib or in combination with other experimental agents during which time the patients experienced a clinical benefit as assessed by his her treating physician and corroborated by radiographic assessment at least one ct scan following at least 4 weeks of <regimen> demonstrating stable disease or response on erlotinib therapy
history of anaphylaxis or known intolerance to atropine sulphate or loperamide or appropriate antiemetics to be administered in conjunction with <regimen> irinotecan 5 fluorouracil leucovorin
i iv for ovarian cancer stage ii iv endometrial cancer or stage iii high risk stage ii for colorectal cancer scheduled to receive adjuvant paclitaxel carboplatin for ovarian or endometrial cancer or <regimen> for colorectal cancer age 20 years old 5
histological or cytologically confirmed solid tumor in a patient for whom the study chemotherapy regimen vincristine plus ifosfamide plus doxorubicin plus etoposide <regimen> vincristine plus doxorubicin plus cyclophosphamide alternating with ifosfamide plus etoposide vdc ie ifosfamide plus vincristine plus actinomycin d iva or ifosfamide plus vincristine plus adriamycin ivad is considered an appropriate treatment
previously completed anthracycline based induction chemotherapy with standard regimens including rituximab cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone r <regimen> dose adjusted da etoposide prednisone vincristine sulfate doxorubicin hydrochloride cyclophosphamide epoch and rituximab r and r hyper cyclophosphamide vincristine sulfate doxorubicin hydrochloride dexamethasone methotrexate and cytarabine cvad patients need a minimum of 6 cycles of treatment initial treatment with pidilizumab must be administered between 30 90 days from last dose of induction chemotherapy
histologically confirmed classical hodgkin s lymphoma treated with <regimen> regimen with pet scan ct performed before during and after treatment and also one of the following
patients must have chl that has not been previously treated patients who have received one dose day 1 cycle 1 of standard doxorubicin hydrochloride adriamycin bleomycin vinblastine and dacarbazine <regimen> or doxorubicin hydrochloride vinblastine dacarbazine avd may be enrolled as long as they completed all the required standard of care baseline studies before enrollment and initiate study therapy by day 15 cycle 1
received one prior line of chemotherapy for metastatic pancreatic ductal adenocarcinoma arm idelalisib <regimen> only
a history of a hypersensitivity reaction to any of temozolomide s components or to dacarbazine <regimen>
patients that have received more than one other systemic or itv adjuvant chemotherapy regimen in addition to temozolomide not including intracavitary <regimen> placement
women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of atorvastatin and <regimen> treatment and a negative result must be documented before start of treatment with atorvastatin or <regimen> whichever is received first by patient
greater than 10 of malignant cells reactive with anti <regimen> by immunohistochemistry
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy whichever is later
patients with known hypersensitivity to any component of the chemotherapy <regimen>
must have available computed tomography ct scans of the chest abdomen and pelvis and a bone marrow biopsy that were performed within 56 days prior to the start of <regimen> in addition they must have written documentation ie copies of original medical notes and radiographic reports describing the pre <regimen> staging evaluation the number of cycles of <regimen> administered the dose of each agent the start and stop dates of each cycle and the post <regimen> response evaluation
however if subject received prior therapy with oxaliplatin they will be eligible to receive the <regimen> regimen
hodgkin s disease patients who relapse after radiation therapy alone or in combination with novantrone oncovin velban and prednisone novp and previously untreated patients with stage iii and iv who are eligible for standard <regimen> therapy
hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine <regimen>
drug specific eligibility criteria based on treatment arms subjects are excluded from the <regimen> arm if they have progressed on prior egfr tki therapy from the akt inhibitor arm s if they have received prior akt inhibitor therapy from the mek inhibitor arm if they have received prior mek inhibitor therapy and from sorafenib arm if they have previously received the drug or have prior history of clinically significant hemoptysis or bleeding diathesis as per principal investigator judgment
all hodgkin s lymphoma patients eligible due to 100 <regimen> positivity of reed sternberg cells
subjects planned to receive a minimum of 3 cycles of <regimen> 14 or <regimen> 21 with or without rituximab for subjects enrolled retrospectively eligibility should be assessed on the profile at time of planning treatment where treatment initiates on or after 01 jan 2005 with specific focus on planned chemotherapy and not outcome or number of delivered cycles
ongoing or planned first line induction therapy with 8 cycles of <regimen> or <regimen>
ras wild type metastatic colorectal cancer patients candidate to receive <regimen> or <regimen> plus panitumumab or <regimen> or <regimen> plus cetuximab as upfront treatment as per clinical practice
the dose of ara c in cycles containing <regimen> should be reduced in the following cases the hematopoietic recovery in the previous cycle has been longer than 28 days
failure of any prior chemotherapy docetaxel and or platinum based chemotherapy but patient has not previously received <regimen> treatment
histologically confirmed new diagnosis of ptcl eligible for <regimen> regimen measurable disease based on cheson 2007 criteria eastern cooperative oncology group ecog performance status
psychiatric psychological disorders absence of inability to provide informed consent serious diseases that prevent treatments with chemotherapy myelofibrosis inclusion criteria reduced intensity conditioning regimen for both <regimen> <regimen> regimens age under 70 years and older than 18 years absence of hla compatible related donor
no prior chemotherapy for brain tumor except polifeprosan 20 with carmustine implant <regimen>
treated with r <regimen> associated with an experimental drug polatuzumab tazemetostat venetoclax entospletinib lenalidomide ibrutinib anti pd1 anti pdl1
history of allergic reactions attributed to compounds of similar chemical or biologic composition to <regimen> or trametinib in combination with gsk2141795
pregnant or breastfeeding female primary ocular melanoma primary mucosal melanoma use of any investigational or other anti cancer drug within 28 days or 5 half lives whichever is longer preceding the first dose of <regimen> and l19 il2 prior radiation to a target lesion unless there has been clear progression of the lesion since radiotherapy 6
previous asct did not achieve at least a partial response pr to a standard salvage regimen eg <regimen> rituximab ifosfamide carboplatin etoposide or r <regimen> rituximab dexamethasone cytarabine cisplatin
no prior chemotherapy with the exception of 1 cycle <regimen> r based on current diagnosis clinical condition and availability feasibility of initiating genasense immunotherapy radiotherapy or investigational therapies for nhl steroid therapy is allowed only if required for maintenance of another chronic disease eg rheumatoid arthritis
any cll and sll patient who has a short remission duration of less than 3 years after prior first line chemo immunotherapy such as the <regimen> regimen also fulfills criteria of high risk cll sll regardless of the presence or absence of cytogenetic abnormalities 2 2
newly diagnosed relapsed or progressing disease after 1 prior treatment with a non platinum based chemotherapy eg <regimen>
prior anthracycline containing combination chemotherapy required prior salvage <regimen> chemotherapy required endocrine therapy
having no prior chemotherapy immunotherapy or radiotherapy except for one cycle of <regimen> or r <regimen>
has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of <regimen> treatment
patients enrolling onto arm a gemcitabine with nab paclitaxel are allowed to have prior <regimen> in combination with bbi608 in the metastatic setting
per good clinical practice any toxicity related to prior therapies that in the opinion of the investigator would potentially be worsened with <regimen> a
r <regimen>
measurable disease must have failed the following regimens mechlorethamine vincristine procarbazine and prednisone <regimen> and doxorubicin bleomycin vinblastine and dacarbazine <regimen>
exclusion criteria anti cancer chemotherapy or biologic therapy if administered prior to the first planned dose of study medication napabucasin or <regimen> within period of time equivalent to the usual cycle length of the regimen
<regimen> chemotherapy
patients receiving either bolus or 48 hr infusion <regimen> cyclophosphamide 750 mg m 2 iv day 1 doxorubicin 25 mg m 2 day iv given as bolus infusion or over 48 hours continuous infusion days 1 2 vincristine 2 mg iv day 1 prednisone po 100 mg 5 days or bolus or 48 hr infusion r <regimen> rituximab 375mg m 2 on day 1 <regimen> as above
no prior therapy with <regimen> or thalidomide
known hypersensitivity to any component of the study drug <regimen> bevacizumab or radiotherapy
subject has had prior therapies with dacarbazine <regimen> or tmz containing regimens
because of the high incidence of <regimen> positivity in infiltrating t cells in hodgkin s disease patients with cluster of differentiation 25 cd25 positive infiltrating t cells will be eligible even if the hodgkin s cells are negative
must have started adjuvant <regimen> chemotherapy within 8 weeks of resection for colorectal carcinoma
patients will need to fulfill the same inclusion criteria for the clinical trial according to section 2 4 1 plus the following receive <regimen> mtx as the sole gvhd prophylaxis approach receive the same regimens as specified in table 2 5 year of transplant from 2010 to 2013 exclusion criteria for the controls karnofsky performance score 70 data for all eligible patients will be used to constitute the control database for this study
nave for their pancreatic cancer body weight 30kg for <regimen> or durvalumab novel
no prior or scheduled <regimen> implant unless area of assessment and planned resection is outside the region previously implanted
known hypersensitivity to dacarbazine <regimen>
patients with colon rectal cancer who first underwent <regimen> <regimen> or sox regimen including oxaliplatin at 85 mg m2 naive patient or those who had already started chemotherapy and had nausea of grade 2 or higher in the last course or an earlier course non naive patient
for this reason women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and 6 months after completion of durvalumab tremelimumab administration or 90 days after the last dose of <regimen> whichever is the longer time period
have a history of hypersensitivity reaction or intolerance to temozolomide or dacarbazine <regimen>
active infectious disease or any other medical condition which might put the patient at significant risk to tolerate 6 courses of <regimen> chemotherapy eg recent myocardial infarction
initiation of second line chemotherapy not consisting of <regimen>
history of greater than or equal to grade 3 allergic reaction to <regimen> patients successfully desensitized to oxaliplatin are eligible or those willing to undergo desensitization during the first two cycles of <regimen> per institutional guidelines
refractory disease or relapse after at least one prior chemotherapy regimen typically a minimum of 6 cycles of <regimen> presence of measurable disease by physical examination ct or ct pet scan
cyclophosphamide doxorubicin hydrochloride vincristine and prednisone <regimen> and cyclophosphamide vincristine and prednisone cvp or <regimen> with rituximab <regimen> r and cvp with rituximab <regimen> is considered
subjects may receive steroids as prophylactic anti emetics per the <regimen> or gemcitabine nab paclitaxel regimen
serious or uncontrolled medical condition such as presence of abnormal or clinically significant cardiac disease such as acute myocardial infarction or unstable angina within 6 months prior to initiation of treatment with <regimen> imatinib serious neurological or psychological conditions such as dementia or epilepsy or uncontrolled active infection
patients with a pathological or clinical diagnosis of pancreatic cancer and beginning or continuing <regimen> or gemcitabine based chemotherapy
patient age is 18 years patient has an eastern cooperative oncology group ecog performance status of 2 patient has a history of dlbcl according to the who classification patient has progressive disease after receiving at least <regimen> r or <regimen> r like first line regimen standard second line therapy <regimen> <regimen> ice or similar salvage regimens inclusive asct patient has progressive disease after receiving at least <regimen> r or <regimen> r like first line regimen and is not considered eligible for intensive salvage therapy including asct because of age co morbidities impossibility to perform asct patient undergoes at baseline new lymphnode or other pathologic tissue biopsy for confirmation of diagnosis and biologic studies bone marrow biopsy is not adequate for this purpose and should be performed only for staging
prior treatment previously untreated or has received a maximum of one cycle of any combination chemotherapy egcyclophosphamide doxorubicin vincristine prednisone <regimen> <regimen> <regimen> doxorubicin cyclophosphamide cytarabine vincristine methotrexate etoposide ifosfamide cytarabine methotrexate <regimen> ivac <regimen> within 4 weeks of study entry
chemotherapy with the <regimen> 4 regimen the current standard treatment it can be modified in the future in the two groups
<regimen> followed by rituximab at time of relapse is considered 2 treatment regimens
renal transplant recipient currently on csa or <regimen> and prednisolone based
first line treatment duration <regimen> <regimen> with anti egfr monoclonal antibody of whom at least 2 3 of cases will have involved panitumumab of at least 3 months
subjects must be receiving a <regimen> based chemotherapy regimen containing 5 fluorouracil and oxaliplatin on a 14 day schedule
<regimen> br requiring further treatment
patients with performance status 0 or 1 not candidates to receive chemotherapy with <regimen> or performance status 2
mibg scintigraphy positive at diagnosis and after induction chemotherapy pre <regimen> evaluation 4
disease progression during or following treatment with at least one platinum containing regimen eg gemcitabine and cisplatin gc methotrexate vinblastine doxorubicin and cisplatin <regimen> carbogem etc
5 x upper limit of normal 3 x uln for <regimen> creatinine within normal institutional limits or creatinine clearance
subjects receiving chemotherapy with concurrent anthracycline and taxane at or <regimen>
patients suffering from locally advanced pancreatic cancer and have started treatment with <regimen> but must stop because of side effects or who declined the <regimen> treatment
history of severe hypersensitivity reaction to capecitabine 5 fu temozolomide or <regimen> will be excluded ieanaphylaxis or anaphylactoid reactions
contraindication to any of the individual components of chemotherapy as per local prescribing information of the selected chemotherapy combination fc <regimen> or bendamustine
peripheral neuropathy grade 1 histologic diagnosis different from hodgkin lymphoma first line treatment with <regimen> compressive symptoms caused by the presence of lymphoma patients treated previously with any anti cd30 antibody
subject with a history of kelodial scar formation a known sensitivity to light photosensitivity or is taking medication that makes the skin more sensitive to light including non steroidal anti inflammatory agents eg aspirins ibuprofens acetaminophen tetracyclines phenothiazines thiazide diuretics sulfonyluraes sulfonamides <regimen> fluorouracil vinblastine griseofulvin alpha hydroxi acids ahas beta hydroxi acids bhas retin a accutane and or topical retinoids
of 0 or 1 life expectancy of 6 months after enrollment patients who have given written consent to take part in the study after detailed explanation of the study prior to enrollment inclusion criteria for randomization patients who have received 6 cycles of <regimen> panitumumab combination therapy patients who are assessed at ecog p s of 0 1 in the 6th cycle
scheduled to receive <regimen> chemotherapy with individual oxaliplatin doses of 85 mg m 2 per cycle given in 2 week cycles egmodified m
treatment with <regimen> or cetuximab within 12 months
prior treatment must include <regimen> cyclophosphamide doxorubicin vincristine and prednisolone like chemotherapy in combination with rituximab
treatment with <regimen> will be definitively suspended even that included in the bea conditioning when previous toxicity include severe cerebellar ataxia confusion or another sign of central nervous toxicity that has not another clear explanation
patient in the first cycle of chemotherapy in adjuvant <regimen> regimen
no medical contraindications to <regimen> chemotherapy or rituximab no prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix no aids or hiv
if the cns is a site of progressive disease on <regimen> treatment of cns lesions is required for enrollment
no selection will be made based on other medical problems or laboratory values except as they affect the patient s eligibility to receive standard r <regimen> chemotherapy as determined by the treating physician
pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with <regimen> or trametinib in combination with gsk2141795
histologically confirmed cd20 mantle cell lymphoma with measurable or evaluable disease no prior chemotherapy immunotherapy or radiotherapy except for 1 cycle of <regimen> like chemotherapy
prior treatment with <regimen> temozolomide or other chemotherapeutic regimens
subjects who are pregnant breast feeding or of reproductive potential who are not employing an effective method of birth control or are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
other than <regimen> first line treatment preceding patient s inclusion
known allergic reactions against foreign proteins subjects for whom 8 cycles of <regimen> might be problematic and have the following findings conditions should not be enrolled
prior therapy with 1 prior systemic therapy over a period of at least 2 months eg at least two 4 week cycles of a regimen such as gemcitabine and nab paclitaxel or at least four 2 week cycles of a regimen such as <regimen> <regimen> or <regimen> candidate for additional therapy consisting of radiation with gemcitabine radiosensitization
as long as the treatment is erlotinib or <regimen> patients can receive multiple regimens of either or both treatments but one of the regimens should be for at least 12 weeks
patients must have histologically confirmed crc with isolated liver metastasis patients must be planned for a hepatic metastasectomy patients must have received at least 3 cycles of chemotherapy <regimen> or <regimen> with or without bevacizumab prior to the planned hepatic metastasectomy primary tumor must be considered resectable with a plan for this to either occur concurrently with the liver resection or subsequent to this
18 years eligible for intensive salvage chemotherapy with r <regimen> <regimen> patient received first line of chemotherapy when dlbcl was initially diagnosed and did not receive any further chemotherapy until enrollment in this study all treatment related toxicities from prior chemotherapy resolved to grade 1or resolved to grade 2 only if deemed clinically not significant and approved by the sponsor 7
known hypersensitivity to 5 fluorouracil leucovorin or oxaliplatin arm idelalisib <regimen> their metabolites or formulation excipients
local investigator decides if initial r <regimen> is needed based on patient s conditions age 18 70 years 6
patients receiving treatment other than r <regimen> or r <regimen> followed by radiotherapy or who have previously been treated for dlbcl will be excluded
patients with histological or cytological confirmation of lymphoma who are previously untreated and are scheduled to receive <regimen> alone
nonrecovery from the toxic effects of <regimen> r therapy
patients previously treated with continuous infusion 5 fu or any schedule of <regimen> dacarbazine which are similar to capecitabine and temozolomide respectively will be excluded
other types of lymphomas egb cell lymphoma contraindication to any drug contained in the three chemotherapy regimens r <regimen> r fc r dha tested positive for hiv active hepatitis b
prior <regimen> placement is not a contradiction to patient enrollment in this trial
<regimen> irb 15 011732 and or <regimen> irb 17 013895
12 weeks as the best response to their 1st egfr tki treatment and who have received any subsequent anti cancer therapy excluding egfr tkis treatment including but not limited to doublet platinum based chemotherapy or <regimen> or <regimen> on which they progressed
for patients enrolled in <regimen> which includes pld prior treatment with pld is not allowed
follicular lymphoma patients previously treated with the combination of rituximab and chemotherapy r <regimen> r <regimen> fludarabine having received rituximab maintenance refractory to a first line excluding radiotherapy or relapsed after having achieved any response to previous treatment 4
patient must have developed disease progression during or following treatment with at least one platinum containing regimen eg gemcitabine cisplatin gc methotrexate vinblastine doxorubicin cisplatin <regimen> carboplatin gemcitabine carbogem for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence or must be unfit or ineligible for cisplatin based chemotherapy there is no restriction on the number of prior lines of chemotherapeutics agents received
sensitivity to temozolomide nitrosoureas or <regimen>
patients must also be able to tolerate standard <regimen> reduced dosing of <regimen> at enrollment is exclusionary
patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis scheduled to undergo ric allogeneic sct with a peripheral blood stem cell graft using fludarabine busulfan <regimen> conditioning and tacrolimus methotrexate <regimen> mtx
patients with following treatment prior to <regimen> chemotherapy immunotherapy or biologic systemic anticancer therapy within 21 days of study entry 42 days for mitomycin and nitrosoureas prior taxanes radiation therapy within 28 days 3 months for bone marrow exposure 20 hormonal therapy within 4 weeks
histologically the first large scaled b cell lymphoma patient diagnosis time 65 years old or older patients planning r <regimen> chemotherapy
cisplatin r <regimen> patients who were previously refractory to rituximab ifosfamide cytarabine etoposide <regimen> stable disease or progressive disease are not eligible to the study or patients in first relapse after autologous stem cell transplant asct or patients not eligible for asct who failed to achieve a cr after at least one prior treatment and no more than 4 previous lines or in relapse after at least one prior treatment and no more than 4 previous lines
patients who are still pet scan positive mid therapy with r <regimen> but have turned negative after completion of therapy
adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive bevacizumab or cetuximab in combination with <regimen> regimen as first line treatment patients who will receive irinotecan a component of <regimen> regimen using camtop injection
pt 1 5 x uln unless subject is receiving anticoagulant therapy as long as pt or ptt is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia activated partial thromboplastin time aptt 1 5 x uln unless subject is receiving anticoagulant therapy as long as pt or ptt is within therapeutic range of intended use of anticoagulants or patient has disseminated intravascular coagulation deemed by investigator to be due to leukemia female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of <regimen> treatment and again prior to d1 of pembrolizumab treatment
20 000 ul hydroxyurea can be overlapped with 5 azacytidine in selected cases after consultation with the study chair hydroxyurea must be discontinued before the initiation of the <regimen> mitoxantrone chemotherapy
exclusion criteria patients with following treatment prior to <regimen> chemotherapy immunotherapy or biologic systemic anticancer therapy within 28 days of study entry
cytologically confirmed measurable and or evaluable advanced stage iii iv colorectal cancer that can be accurately assessed by ct mri scan recist v1 1 for which regimen of <regimen> bevacizumab cetuximab is arranged by the investigator subjects may be treatment nave or may have received therapy for colorectal cancer 4
patients eligible for <regimen> or <regimen> therapy
pathologically confirmed or highly suspected apdac defined as a pancreatic mass on imaging suspected distant metastases no features suggestive of a neuroendocrine tumor and or clinico biological abnormalities compatible with the diagnosis of apdac age 18 years patients with ecog ps 2 and clinico biological features precluding initial therapeutic clinical trial and or treatment with <regimen> or gemcitabine nab paclitaxel no prior history of cancer except in situ breast cervix cancer or basal cell carcinoma and or complete remission for more than 3 years from another cancer
previous anticancer therapy including <regimen> and palliative radiotherapy must be completed at least three weeks prior to the dose of js001
scheduled for oxaliplatin treatment in <regimen> based chemotherapy regimen
histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective <regimen> is a reasonable treatment in the judgement of the investigator measurable disease as per recist v1 1 criteria able to swallow oral medication as an intact dosage form
cetuximab based chemotherapy monotherapy combination therapy with cytotoxic chemotherapy such as <regimen> <regimen> irinotecan <regimen> <regimen> first line second line or third line are all eligible
either <regimen> or <regimen> is allowed
histologically confirmed hodgkin s lymphoma or non hodgkin s lymphoma receiving q14 q21 or q28 day <regimen> ice <regimen> or <regimen> chemotherapy with or without rituximab
treated on resort trial ecog e4402 comprising <regimen> and then randomized to rituximab maintenance therapy or retreatment with rituximab upon disease relapse
treated with bis chloroethylnitrosourea etoposide cytarabine and cyclophosphamide <regimen> or bis chloroethylnitrosourea etoposide cytarabine and melphalan beam lymphoma diagnosis melphalan myeloma diagnosis before stem cell transplantation sct
with recurrent or relapsed dlbcl after r <regimen> like theraphy as the firstline therapy
all medical geographical social and psychological conditions or a legal situation that will not allow the patient to finish the study or sign an informed consent form relating to the chemotherapy <regimen>
adjuvant or neoadjuvant chemotherapy with docetaxel regimens <regimen> or anthracyclines followed by docetaxel 100 mg m2 x 4
for patients with rhgg the patient intends to undergo treatment with the <regimen> at the time of planned resection ie on study surgery or has received the <regimen> 30 days from the date of planned resection
recurrence within 12 months of adjuvant therapy with <regimen> or a similar regimen ie <regimen> <regimen> is considered one regimen and allowed for study
iv previously treated with at least one line of prior therapy <regimen> or <regimen> like measurable disease age 19
history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or <regimen> history of gastrointestinal disease or significant bowel resection that could interfere with drug absorption
diagnosis of non hodgkin s lymphoma where therapy with <regimen> plus rituximab is considered
no prior lymphoma treatment with one exception one cycle of r <regimen> regimen is permitted consisting of one single dose each of rituximab of cyclophosphamide of doxorubicine and of vincristine as well as up to 5 doses of prednisone when part of chemotherapy
prior polifeprosan 20 with carmustine implant <regimen> allowed at discretion of principal investigator
patients eligible for erbitux and <regimen> treatment k ras wild type tumour
no more than one prior cycle of r <regimen> chemotherapy
no prior <regimen>
subject intends to undergo treatment with the <regimen> at the time of this surgery
<regimen> for the treatment of cll in the presence of deletion chromosome 17 del 17p or tumor protein p53 tp53 mutation in adult patients who are unsuitable for or have failed to a bcell receptor pathway inhibitor
no prior medical therapy chemotherapy immunotherapy biologic or targeted therapy or radiation therapy for the current colon cancer except for one cycle of <regimen>
subject must be receiving a calcineurin inhibitor cni based cyclosporine csa any formulation or tacrolimus <regimen>
patient is treatment nave or currently receiving front line chemotherapy with <regimen> or gemcitabine abraxane and has stable disease
subject meets the criteria per investigator s institution to receive soc r chemotherapy ie r <regimen>
according to investigators evaluation the subjects must have documented radiological progression of disease during <regimen> treatment
concurrent investigational corticosteroid therapy or any other anti cancer treatments such as chemotherapy radiation biologic or investigational therapies while receiving protocol therapy other than one cycle <regimen> r allowed based on current diagnosis clinical condition and availability feasibility of initiating genasense other than chronic steroid use for another indication for stage i ii or as clinically indicated involved field irradiation as per standard practice is accepted
68 69 r <regimen> chemoimmunotherapy may be given every 14 days or every 21 days
patient treated with <regimen> or <regimen> in 1st line
treatment plan to receive standard <regimen>
female patients who are pregnant or breast feeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab and tremelimumab combination therapy or 90 days after the last dose of <regimen>
patients refractory to <regimen> in a prior treatment line
6 cycles of immunochemotherapy for example rituximab chemotherapy <regimen> or <regimen> like and must have relapsed or refractory disease at the time of trial entry
<regimen> prograf or advagraf corticosteroids and either mmf cellcept ec mps myfortic aza imuran or srl rapamune at the baseline visit
any condition or comorbidity that in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results including but not limited to major surgery 28 days prior first dose of study treatment anticancer treatment during the last 30 days prior to start of <regimen> treatment including systemic therapy or major surgery palliative radiotherapy has to be completed at least 2 weeks prior to start of study treatment
exclusion criteria patients who have been off of <regimen> or gemcitabine abraxane therapy for more than 49 days patients who have had more than one line of chemotherapy patients with uncontrolled intercurrent illness including but not limited to ongoing or active infection systematic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements patient who have had prior treatment with il 2 interferon anti pd 1 anti pd l1 anti pd l2 anti cd137 anti ox 40 anti cd40 or anti ctla 4 antibodies patients receiving active immunosuppressive agents or chronic use of systemic corticosteroids within 14 days prior to first dose of study drug patients who have received growth factors including but not limited to granulocyte colony stimulating factor g csf granulocyte macrophage colony stimulating factor gm csf erythropoietin
melphalan 140 mg m2 or 200 mg m2 beam <regimen> <regimen> or cbv
failed flu cy rituximab <regimen> combination chemotherapy at any time point or
known hypersensitivity to any of the study drugs study drug classes excipients in the formulation or to dacarbazine <regimen>
disease not refractory to first line f fc <regimen> b br if received such therapy
bevacizumab or <regimen>
ann arbor stage ii iii or iv dlbcl according to the real who classification from initial diagnosis made prior to starting <regimen> r therapy
patient is planned to receive fludarabine containing regime <regimen> chemotherapy after apheresis of pbmc which is planned to be the last cycle of <regimen> chemotherapy no further <regimen> chemotherapy should be planned within 3 months after this cycle of <regimen> definition of poor prognosis in aml high risk mds a patient with aml has a poor prognosis if any of the following is satisfied
previous <regimen> treatment for patients who will be included in the <regimen> cohort apart from <regimen> treatment in an adjuvant setting
subjects receiving <regimen> <regimen> cytoxan hydroxyrubicin adriamycin oncovin vincristine etoposide prednisone chemotherapy or
no prior monoclonal antibody therapy for lymphoma except if included in a single course of <regimen> <regimen> r
not pregnant or nursing because of the unknown effects of <regimen> r or siplizumab on the developing fetus and infant
standard dose of bevacizumab 5 mg kg may be administered prior to <regimen> infusion per investigator decision for as long as permanent decision to include or exclude bevacizumab is made prior to patient randomization
patients on trastuzumab should continue <regimen> per standard of care the dosing and schedule of trastuzumab should follow standard guidelines as described below trastuzumab 2mg kg iv weekly or trastuzumab 6mg kg iv
patients with contra indication to chemotherapy <regimen> and <regimen>
previous chemotherapies with <regimen> regimen
patients undergo postoperative adjuvant treatments except chemotherapy of <regimen>
patients must have a treatment plan to include r <regimen> or r <regimen> followed by radiotherapy
<regimen> or <regimen> like anthracycline containing treatment for dlbcl within 6 months prior to registration
having failed first line treatment with <regimen> based chemotherapy full recovery from all prior therapies
inclusion criteria at randomization patients on <regimen> mmf steroids
platelet count 100 x 109 l unless due to splenomegaly bone marrow involvement with lymphoma or due to initiation of r <regimen> chemotherapy
subjects who did not respond to prior <regimen> therapy relapsed within 6 months of the last dose
previous treatments such as surgery radiofrequency ablation transarterial liver embolization somatostatin analogs interferon everolimus or other targeted therapy peptide receptor radionuclide treatment prrt and chemotherapy platin etoposide <regimen> paclitaxel or docetaxel are allowed
first line treatment of dlbcl must have been 6 or 8 cycles of standard <regimen> chemotherapy cyclophosphamide 750 mg m2 doxorubicin 50 mg m2 vincristine 1 4 mg m2 up to a maximum of 2 mg on day 1 and at least 40 mg m2 day prednisone on days 1 to 5 every three weeks with generally accepted adjustments in dose or frequency due to toxicity patient scheduling etc
mean qt interval corrected for heart rate using fridericia s formula qtcf 470 ms calculated from 3 ecgs within 15 minutes at 5 minutes apart for <regimen> and durvalumab tremelimumab combination studies this criterion can be removed
age 18 and 70 years patients classified as having ra according to the 1987 acr classification criteria inadequate clinical response to <regimen> defined as moderate high active disease after oral or s c
complete remission cr or unconfirmed complete remission cru according to the international workshop response criteria for nhl described by cheson et al and modified for this study after first line treatment with <regimen> r ct scans of chest abdomen pelvis and neck if applicable must have been performed within 6 weeks after the last dose of the last course of <regimen> r applicability of the neck ct means that the patient had involvement of the neck region by palpation physical examination at first diagnosis pre <regimen> r
<regimen> for the treatment of cll in the absence of del 17p or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a bcell receptor pathway inhibitor
b exclusion from the additional population scheduled to receive any concomitant chemotherapeutic agent other than <regimen> or <regimen> agents
subjects who are expected to receive toxicity test at least once after <regimen> treatment
recipient of frontline multi agent chemotherapy for example <regimen> dose adjusted <regimen> <regimen> rice <regimen> investigational agent etc eligible patients will have recently received 4 months from end of treatment assessment be actively receiving or planned to receive frontline chemotherapy in near future within 3 months of signing consent a frontline therapy program can include different sequential phases of treatment including high dose therapy and autologous stem cell transplantation
all stages of <regimen> expressing t cell leukemia and lymphoma eligible except stage
pre treatment other than 1 cycle <regimen> or similar 1 week of another chemotherapy
men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study for the duration of study participation and 6 months after completion of durvalumab tremelimumab administration or 90 days after the last dose of <regimen> whichever is the longer time period
cardiopulmonary dysfunction or liver and kidney dysfunction and unable to tolerate <regimen> chemotherapy
refractory to or relapsed within the previous 3 months after therapy with an <regimen> or <regimen> containing regimen
stage i or ii of nodal dlbcl treated with r <regimen> definition of primary breast dlbcl
grade 2 according to nci common terminology criteria for adverse events version 4 0 ctcae v 4 0 known history of human immunodeficiency virus hiv infection presence of acute or chronic liver disease renal disease or pancreatitis known history of chronic hepatitis b or c symptomatic metastatic brain or meningeal tumors unless the patient is 6 months from definitive therapy has a negative imaging study within 4 weeks of <regimen> initiation and is clinically stable with respect to the tumor at the time of study entry
patient eligible for a standard second line treatment with <regimen>
treatment with <regimen> <regimen> and biotherapy anti egfr epidermal growth factor receptor erbitux planned patient already enrolled in an other clinical trial with another first line of chemotherapy
the patient must be enrolled within 56 days of the first day of the last cycle of <regimen> chemotherapy and within 35 days following response evaluation after <regimen> chemotherapy
treatment planning including 6 adjuvant ct courses with the first 3 being necessarily of the fac50 fec100 or <regimen> type
<regimen> cohort anti pd 1 pd l1 nave patients who have received 1 to 2 prior lines of cytotoxic chemotherapy including a platinum doublet containing regimen expansion cohort s
treatment naive except for prior radiation or a single cycle of <regimen>
no prior or concurrent polifeprosan 20 with carmustine implant <regimen>
patients must not have received prior irinotecan based chemotherapy egirinotecan hydrochloride leucovorin calcium fluorouracil and oxaliplatin <regimen> or <regimen>
contraindication to any of the individual components of <regimen> cyclophosphamide vincristine doxorubicin and prednisone including prior anthracycline treatment
patients may be entered in the study only if they meet all of the following criteria male or female patient greater than or equal to 18 years of age histologically or cytologically confirmed nonresectable locally advanced or metastatic colorectal adenocarcinoma patients must have failed a first line chemotherapy regimen for nonresectable locally advanced or mcrc first line 5 fu based therapies including but not limited to <regimen> <regimen> 4 <regimen> <regimen> single agent capecitabine infusional 5 fu or other chemotherapies
known hypersensitivity to any component of tmz or decarbazine <regimen>
previous adjuvant <regimen> based chemotherapy is allowed
<regimen> after progression to adjuvant <regimen> occurred on treatment or within 6 months after treatment completion
previous attendance in the active treatment groups any <regimen> classes ever taken or cbt in the past 3 years
off <regimen> treatment for more than 70 days prior to treatment on study prior chemotherapy for metastatic pancreatic cancer other than <regimen> or adjuvant therapy
the following exclusion criteria are relevant for patients who will be treated with rgx 202 01 plus <regimen> per protocol on both dose escalation and dose expansion cohorts the patient has known dihydropyrimidine dehydrogenase dpd deficiency or is on treatment with dpd inhibitors including sorivudine or its chemically related analogues such as brivudine within 4 weeks prior to the start of <regimen> treatment
previously treated with a fludarabine plus alemtuzumab <regimen> regimen for b cll
women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence for the duration of study therapy and for 3 months after the last dose of amg 337 plus <regimen> chemotherapy should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately should a man impregnate or suspect that he has impregnated a woman while participating in this study he should inform his treating physician immediately
prior radiation prior biological therapy or prior chemotherapy other than first line <regimen>
use of prior chemotherapy with other agents except adjuvant chemotherapy with <regimen> since completed more than 6 months
<regimen> myeloablative mel thiotepa fludarabine
double hit dlbcl mantle cell lymphoma any transformed low grade b cell lymphomas or grade 3 follicular lymphoma grade 3a or 3b who were refractory to <regimen> like or any anthracycline based chemotherapy or relapsed after at least one prior combination chemotherapeutic regimen and who are deemed candidates for a salvage type chemotherapy
subjects who received at least one standard chemotherapy for advanced soft tissue sarcoma an anthracycline or an <regimen> or a combination therapy
treatment with experimental drugs in combination with <regimen>
previous adjuvant <regimen> chemotherapy
patients with aggressive nhl refractory to or relapsed from at least one <regimen> based therapy who have had prior treatment with rituximab and who are not candidates for high dose chemotherapy or autologous stem cell transplantation
seven consecutive days of steroids alone or in combination with a non <regimen> regimen necessary for patient stabilization eg cyclophosphamide and steroids steroids for normalization of disease related hyperbilirubinemia
prior treatment previously untreated or who received a maximum of one cycle of combination chemotherapy ier <regimen> <regimen> or r <regimen> within 4 weeks of study entry except patients who require dose reduction after the first cycle of off study <regimen>
refractory to 1 fludarabine containing regimen is defined as failure to achieve at least pr to the last fludarabine containing regimen received or disease progression while receiving the last fludarabine containing regimen or disease progression in responders ie achieved a pr or cr within 6 mos of the last cycle of the last fludarabine containing regimen received eg <regimen> fr or fc or in responders ie achieved a pr or cr within 24 mos of the last cycle of <regimen>
prior rituximab or other monoclonal immunotherapy permitted and eligible for <regimen>
histologically proven diffuse large b cell or follicular b cell non hodgkin s lymphoma for which chemotherapy with rituximab <regimen> chemotherapy is considered treatment of choice
4 to 8 cycles r <regimen> like total of 8x rituximab
no evidence of progressive disease while on r <regimen> chemotherapy
previous treatment for metastatic disease is limited to <regimen> bevacizumab
cohort 2 no prior tmz or <regimen> wild type gnaq gna11 status
eligible to receive chemotherapy with <regimen> or <regimen> after a short chemotherapy interruption 3 to 4 weeks
cd20 positive diffuse large b cell lymphoma undergoing treatment with systemic rituximab in combination with <regimen> <regimen> or epoch and deemed high risk of cns relapse and eligible for central nervous system prophylaxis with intrathecal therapy
patient must be a candidate to receive at least 2 doses of <regimen> chemotherapy
use of a <regimen> based combination regimen is permitted with 1 anti angiogenic agents such as bevacizumab or 2 targeted therapy such as anti epidermal growth factor receptor agents <regimen> based regimens will not be allowed
b cell non hodgkins lymphoma nhl planned to receive at least 2 cycles of <regimen> 14 <regimen> 14 <regimen> di 14 <regimen> or <regimen> 21
has at least two planned consecutive 21 day cycles with 75 mg m2 <regimen>
previously untreated or treated with up to 3 cycles of standard dose 3 weekly r <regimen> chemotherapy prior to enrollment iepatients may be enrolled prior to initiation of the fourth cycle of r <regimen> chemotherapy
may be enrolled in this study after the first cycle of r <regimen> if all screening evaluations were performed prior to the first cycle of chemotherapy
refractory to obinutuzumab defined as progression or relapse 12 months of receiving <regimen> or 24 months of receiving an obinutuzumab containing regimen
history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to <regimen>
received at least one combination chemotherapy regimen with rituximab such as r <regimen> r <regimen> or equivalent
exclusion criteria liver directed therapy chemoembolization radioembolization bland embolization ablative therapy within 4 weeks of <regimen>
received and failed potentially curative chemotherapeutic regimens eg <regimen> <regimen> or <regimen>
prior treatment with nivolumab ipilimumab or with any other anti pd 1 anti pd l1 anti pd l2 anti ctla 4 antibody or any other antibody or drug specifically targeting t cell co stimulation or immune checkpoint pathways nb participant is eligible for part 2 of the study if they took <regimen> in part 1 of the study
rituximab cyclophosphamide doxorubicin hydrochloride hydroxydaunomycin vincristine sulfate oncovin prednisone r <regimen> with or without alternating rituximab dexamethasone cytarabine ara c cisplatin platinum r <regimen> with or without autologous auto stem cell transplant sct
chronic systemic steroid use including <regimen> therapy or as part of any regular cancer treatment however steroids used as prophylaxis for nausea and vomiting are allowed to prevent rash with alimta low dose dexamethasone will be allowed
if younger than 40 there must be comorbidities which preclude the patient to undergo <regimen> conditioning regimen
suitable for first line therapy with oxaliplatin leucovorin calcium and fluorouracil <regimen> 6
inclusion criteria age 18 65 relapsed refractory disease after receiving one line of standard chemoimmunotherapy r <regimen> ga <regimen> r <regimen> like diffuse large b cell lymphoma at relapse
14 or 21 or r <regimen> or r <regimen> of 6 cycles
patients must undergo systemic treatment with m <regimen> or nab paclitaxel as a first line standard systemic palliative treatment or combination treatment with m <regimen> or nab paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment
patients planning to receive <regimen> or having already received <regimen> and having signed consent to enroll in the registry within 14 calendar days after surgery for treatment of central nervous system cns tumor s or are currently enrolled in another study where they received <regimen>
further at the investigator s discretion and for patients who are unstable one cycle of r <regimen> is allowed prior to enrollment but no more than one cycle
gastric gej or esophageal adenocarcinoma for which treatment with folfox6 <regimen> <regimen> or irinotecan would be acceptable as determined by the investigator
patients will be enrolled on this trial after resection of hepatic metastases combined with <regimen> or <regimen>
patients will be eligible if the treatment phase consisting in a rituximab combined with any anthracycline containing chemotherapy regimen without consolidation with autologous stem cell support eg 6 cycles of <regimen> 21 <regimen> mega <regimen> or 12 weeks of vacop b or <regimen>
the patients are defined as locally advanced pancreatic cancer according to nccn guideline the patients prescribed <regimen> based neoadjuvant therapy
inclusion criteria diagnosed as primary hcc primary icc or secondary liver cancer confirmed by pathological findings clinical features or radiographic examinations according to american association for the study of the liver diseases aasld guidelines age above 18 years about to receive <regimen> treatment with callispheres according to clinical needs and patients willing
known dihydropyrimidine dehydrogenase dpd deficiency major surgical procedure open biopsy or significant traumatic injury within 28 days before start of day 1 of treatment with <regimen>
biopsy proven lymphoma for which rituximab etoposide prednisone vincristine sulfate cyclophosphamide and doxorubicin hydrochloride <regimen> is appropriate frontline therapy eg burkitt lymphoma or diffuse large b cell lymphoma dlbcl nhl including plasmablastic lymphoma and primary effusion lymphoma but not t cell lymphoma tissue histology will be reviewed at the treating institution
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
prior polifeprosan 20 with carmustine implant <regimen> or gliasite brachytherapy
patients must have received at least 1 prior rituximab based immunochemotherapy eg r <regimen> <regimen> etc
patients may enroll anytime within the first 2 cycles of <regimen> or after pet 2
prior <regimen> or single agent irinotecan is prohibited
4 months of first line chemotherapy with either <regimen> <regimen> or <regimen> with or without bevacizumab
relapsed or refractory dlbcl in which all participants must have received at least one potentially curative established immunochemotherapy lymphoma regimen that contained rituximab egr <regimen> <regimen> r <regimen> r <regimen> participants must also have failed or be ineligible for salvage high dose therapy
at least 1 year since prior <regimen> 4 or <regimen> regimen in the adjuvant setting
subject has follicular lymphoma or marginal zone lymphoma that has progressed after at least 2 lines of treatment with combination chemoimmunotherapy egr bendamustine r <regimen>
no prior chemotherapy except for <regimen> gem abrax or gem cap
received at least two previous treatment regimens for fl or relapsed or progressed while on or following cyclophosphamide doxorubicin vincristine and prednisone <regimen> or anthracycline based regimen for dlbcl subjects solid tumor subjects must have histologically or cytologically confirmed solid tumor that is either measurable or evaluable and refractory to standard treatment or fow which no curative treatment exists
patient planning to receive treatment with <regimen> or gem nab p chemotherapy with or without investigational agents
the patient is a candidate for <regimen>
disease progression during or following treatment with at least one platinum containing regimen eg gemcitabine and cisplatin gc methotrexate vinblastine doxorubicin and cisplatin <regimen> carboplatin and gemcitabine carbogem etc
t cell histiocyte rich dlbcl subject is considered an appropriate candidate per investigator assessment for induction therapy with 6 cycles of r <regimen> 21 immunochemotherapy
for relapsed patients two lines of a standard chemotherapy bep or ep in first line treatment <regimen> or vip in second line treatment
patients who received chemotherapy <regimen> including bevacizumab
previously treated with 5 fu based chemotherapy in the form of <regimen> <regimen> or <regimen> plus bevacizumab
history of hypersensitivity to tmz or any of its excipients or to dacarbazine <regimen>
female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy
subject is taking medication known to induce photosensitivity including non steroidal anti inflammatory agents tetracyclines phenothiazines thiazide diuretics sulfonylureas sulfonamides dacarbazine <regimen> fluorouracil vinblastine and griseofulvin within 4 weeks of therapy
requires treatment with oxaliplatin as part of a <regimen> regimen
expected communication between ventricle and resection cavity that cannot be repaired in order to safely use <regimen>
contraindicative to any drug in <regimen> or to anthracycline patients with diabetes and intolerant to the prednisone in this study
prior treatment with dacarbazine <regimen> or temozolomide tmz
not amenable to curative surgical therapy for whom <regimen> can be considered a standard treatment
ict should have comprised rituximab combined with fludarabine with or without an alkylating drug with or without an anthracycline ex fludarabine rituximab fluda cyclophsphamide rituximab <regimen> mitoxantrone r bendamustine
100 000 mm 3 platelets 75 000 required for patients who received cycle 1 of <regimen> prior to registration
histologically proven colorectal adenocarcinoma intended treatment with <regimen> after one prior palliative chemotherapy for metastatic crc age 18 years metastatic disease not suitable for curative intent surgery measurable
current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses which are not to exceed 10 mg day of prednisone or an equivalent corticosteroid receipt of the last dose of anti cancer therapy chemotherapy immunotherapy endocrine therapy targeted therapy biologic therapy tumor embolization monoclonal antibodies other investigational agent 21 days prior to the first dose of study drug history of allogeneic organ transplant uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure uncontrolled hypertension unstable angina pectoris cardiac arrhythmia active peptic ulcer disease or gastritis active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis b hepatitis c or human immunodeficiency virus hiv or psychiatric illness social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
patient is currently receiving treatment with dabrafenib <regimen> or combination within a novartis or former gsk sponsored study which has fulfilled the requirements for the primary objective
malin lymphoma hodgkin or not treated with anthracyclines for at least 6 cycles adriamycin bleomycin vinblastine and dacarbazine <regimen> or <regimen> cyclophosphamide hydroxydaunomycin oncovin and prednisone <regimen> et rituximab r <regimen> minichop et rminichop <regimen> having received or not an intensification with autologous hematopoietic stem cell transplantation in first line
receipt of neoadjuvant or adjuvant <regimen> therapy
inclusion criteria patients with a diagnosis of previously untreated aggressive non hodgkin s lymphoma including patients with mantle cell lymphoma who will be or are receiving treatment with r <regimen> and r ara c mtx patients
prior therapy with regimens containing dacarbazine <regimen> or tmz is not permitted
i or ii mandatory pet scan performed at diagnosis patients treated with first line <regimen> and pet scan positive after 2 cycles deauville score 4 6
allowed provided patient had a remission duration of 1 year after administration of any established multi agent chemotherapy regimen eg cvp <regimen> or rituximab in combination with <regimen>
eligible for <regimen>
have had at least 1 prior treatment for all gi tumors except for small bowel adenocarcinoma as <regimen> can be considered standard first line therapy for that particular tumor
5 fluorouracil leucovorin with oxaliplatin <regimen> or <regimen> a treatment with trastuzumab is allowed in association
male patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception ie double barrier method condom plus spermicidal agent starting with the first dose of study therapy through 6 months 180 days after the last dose of durvalumab and tremelimumab combination therapy or 90 days after <regimen> is discontinued whichever is longer
patients previously treated with continuous infusion 5 fu or any schedule of <regimen> which are similar to capecitabine and temozolomide respectively will be excluded
one two courses of r <regimen> combination as upfront therapy are admitted in patients with large amount
patients undergo chemotherapy of <regimen>
and or cooperate with the study investigator any investigational drugs within 30 days before enrollment in the study or foreseen use of investigational agents during the study patient with any type of ostomy any previous radiotherapy to the abdomen or pelvis scheduled to receive radiotherapy to abdomen or pelvis during the study day 1 to day 14 scheduled to receive any concomitant chemotherapeutic agent other than <regimen> or <regimen> agents oxaliplatin irinotecan folinic acid 5 fu from day 1 to day 14 previous use or scheduled to receive monoclonal antibodies egbevacizumab cetuximab etc during the study from day 1 to day 14 major surgery within the previous 3 weeks any type of condition leading to chronic diarrhea including but not limited to inflammatory bowel diseases egulcerative colitis and crohn s disease chronic diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome any diarrhea in the 48 hours preceding study drug administration use of anti diarrheal agents within the 48 hours prior to study drug administration use of laxatives within 7 days prior to study drug administration use of antibiotics within 7 days prior to study drug administration history of chronic 30 consecutive days use of laxatives active and ongoing systemic infection lactating woman history of hypersensitivity or allergies to drugs or compounds potentially related to this investigational drug class previous exposure to glp 2 or other compounds in this investigational drug class abnormal laboratory values including
other severe medical conditions contraindication of <regimen> paclitaxel and gemcitabine 3
subject must have relapsed following or be refractory to 1 standard treatments such as fludarabine based regimens f fc fr <regimen> alkylator chlorambucil bendamustine based regimens or bruton s tyrosine kinase inhibitor ibrutinib or relapsed or refractory indolent non hodgkin lymphoma or aggressive non hodgkin lymphoma for waves 1 2 or 3 unless otherwise indicated
the <regimen> chemotherapy should consist of standard doses of each agent although dose reduction is permitted
prior treatment with <regimen> or single agent irinotecan is prohibited within six weeks of enrollment
subjects must satisfy all of the following criteria have histologically confirmed dlbcl including primary mediastinal b cell lymphoma with relapsed or refractory disease following at least 2 lines of prior standard therapy including alkylator anthracycline unless anthracycline based chemotherapy is contraindicated anti cd20 based therapy rituximab plus cyclophosphamide doxorubicin vincristine and prednisone r <regimen> or equivalent and must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation asct as defined by meeting at least 1 of the following criteria
have a carmustine implant eg <regimen> have uncontrolled hypertension sbp 140 mmhg or dbp 90 mmhg for more than 1 week
foscarnet cidofovir <regimen> acyclovir valaciclovir famciclovir penciclovir lobucavir antisense compound
exclusion criteria patients with contraindication to use <regimen> chemotherapy and pelvic radiation
females of childbearing potential who are sexually active with a non sterilized male partner must agree to use at least 1 highly effective method of contraception from the time of screening until 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen>
at least 6 months since prior adjuvant neoadjuvant methotrexate vinblastine doxorubicin and cisplatin <regimen> or cisplatin methotrexate and vinblastine cmv or cisplatin as a radiosensitizer endocrine therapy
and or bcr abl positive includes patients initiated on first course of <regimen> before cytogenetics known these groups will be analyzed separately
treatment with cetuximab in first line chemotherapy combined with <regimen> or <regimen>
eligible are the cancers for which gemcitabine has been approved in 4 week schedule 1 000mg m2 weekly for 3weeks followed by 1 week rest at the 4th week including non small cell lung cancer pancreatic cancer biliary cancer and urothelial cancer to which <regimen> is considered to be appropriate
lack of pet scans performed in accordance with inclusin criteria during <regimen> treatment
initiation of a first line of chemotherapy by <regimen> or gemcitabine or in combination with nab paclitaxel
patients with previously untreated diffuse large b cell lymphoma dlbcl who are scheduled to receive rituximab 375 mg m 2 plus <regimen> cyclophosphamide hydroxydaunorubicin also called doxorubicin or adriamycin oncovin vincristine prednisone or prednisolone chemotherapy or previously untreated follicular non hodgkin lymphoma nhl who are scheduled to receive rituximab 375 mg m 2 plus cvp cyclophosphamide vincristine prednisolone chemotherapy
non resectable metastatic melanoma of low burden disease and normal ldh who have undergone at least two treatment lines including chemotherapy <regimen> temodal taxanes platinum compounds anti ctla 4 ipilimumab and b raf inhibitor if harboring the v600e braf mutation in their tumor
r <regimen> or <regimen> for dlbcl cohort 2
disease relapse within 12 months after completing therapy with a regimen containing flu or another nucleoside analog 2 failed flu cyclophosphamide cy rituximab <regimen> combination chemotherapy at any time point or 3 have 17p deletion cytogenetic abnormality patients should have received induction chemotherapy but could be transplanted in first 1st cr
candidate for systemic therapy with <regimen> bvz
no more than 1 prior combination chemotherapy regimen chemotherapy consisted of cyclophosphamide doxorubicin vincristine and prednisone <regimen> or a <regimen> like regimen <regimen> or other similar regimen
diagnosed by pathology as gastrointestinal carcinoma and no previous <regimen> or <regimen>
unable to receive r <regimen> chemotherapy
indication of treatment according to the <regimen>
first line irinotecan based <regimen> or <regimen> cetuximab containing therapy producing at least a partial response
received <regimen> chemotherapy and got cr before radiotherapy
patients with metastatic colorectal cancer are eligible for this study colorectal cancer should have been previously confirmed by pathology or cytology to be eligible for this protocol patients should be receiving ziv aflibercept plus <regimen> as a standard treatment prior to enrolling on this trial the number and type of therapy administered prior to enrollment will not affect the ability to enroll on this study
documented advanced stage non hematologic malignancy for whom <regimen> is a reasonable treatment option
intent to treat the patient with a leucovorin calcium fluorouracil and oxaliplatin <regimen> chemotherapy regimen containing fluorouracil 5 fu leucovorin and oxaliplatin according to clinical standard practice the intent should be to dose oxaliplatin at 85 mg m 2 on an every 2 week basis
subjects must have had first line treatment consisting of rituximab with or without rituximab maintenance therapy ierituximab monotherapy r <regimen> r <regimen> fnd etc
hbv core antibody igg anti hbc antibody positive patients with documented hbv reactivation definite or presumptive occurring during treatment at least two cycles of r <regimen> or <regimen> or within 12 months after the last dose of rituximab
failed 1 standard chemotherapy or chemoimmunotherapy regimen eg dacarbazine or <regimen>
<regimen> r
hiv human immunodeficiency virus uncontrolled psychiatric disorder or altered mental status precluding informed consent or necessary testing consumption of herbal preparations supplements except for a daily multivitamin mineral supplement not containing herbal components within 2 weeks prior to the start of cycle 1 of <regimen> bevacizumab cetuximab administration significant cardiovascular disease including active clinically symptomatic left ventricular failure active hypertension
patients with any locally advanced or metastatic gastrointestinal malignancy which <regimen> is indicated for treatment
<regimen> comprising leucovorin calcium fluorouracil and oxaliplatin 2 week course
planned graft versus host disease gvhd prophylaxis consisting of tacrolimus <regimen> methotrexate mtx or <regimen> sirolimus srl
ongoing or planned first line treatment with 6 cycles of <regimen> <regimen> plus cetuximab
the investigator believes the subject is tolerating treatment with oral <regimen> and continued oral azacitidine treatment is of benefit to the subject
eligible to a treatment by immunochemotherapy like r <regimen> r <regimen> or r <regimen> like
previous treatment with chemotherapy or radiation with the exception of up to 1 cycle of <regimen> chemotherapy
<regimen> they should have received 8 cycles
patients on <regimen> or combined treatment with a biological agent or patients on biological treatment monotherapy who show or have ever shown intolerance or poor compliance or safety issues with methotrexate
candidates for systemic therapy with <regimen> and bevacizumab based on the opinion of the primary treating medical oncologist
history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of <regimen> or obinutuzumab
patients must not have received infusional chemotherapy eg <regimen> or similar regimen prior to enrollment
for those patients who have had <regimen> last dose must be greater than 90 days prior to beginning study treatment
first line chemotherapy with an agent other than <regimen> tmz as monotherapy or a combination that may but need not include <regimen> tmz il 2 or ifn group me2
treatment with <regimen> x 4 early stage
adriamycin cyclophosphamide vincristine procarbazine prednisone <regimen> regimen and radiotherapy if applicable
recently completed r <regimen> therapy and achieved remission
participants who have received more than one 1 prior cycle of chemotherapy similar to cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone <regimen> or epoch with or without rituximab
during the run in period of 6 months starting from the date of the first randomization in the trial in case of direct randomization into maintenance phase patient must have been treated in first line by 6 8 cycles of r <regimen>
prior tmz or <regimen> is only allowed in those patients enrolled into the prior chemotherapy cohort
patients should receive at least 4 cycles of r <regimen> chemotherapy
patients must have documented alk positivity at the time of initial <regimen> using the vysis break apart fish assay or other food and drug administration fda approved diagnostic test samples are deemed to be fish positive if greater than or equal to 15 of scored tumor cells
any medical contraindications or previous therapy that would preclude treatment with either irx 2 <regimen> or 2 or the surgery reconstruction or adjuvant therapy required to treat the oral tumor appropriately
doxorubicin bleomycin vinblastine and dacarbazine <regimen> <regimen> abv stanford 5 or refractory to a second line regimen such as mesna ifosfamide mitoxantrone and etoposide mine etoposide methylprednisolone high dose cytarabine and cisplatin
previous treatment with <regimen> or other chemotherapy regimen containing both cladribine and cytarabine
metastatic disease not amenable to surgical curative treatment and eligible to receive therapy with <regimen> leucovorin 5 fluorouracil oxaliplatin bevacizumab
absence of partial response after having received salvage post induction chemotherapy including <regimen> r
pts must have failed standard of care soc therapy w rituximab plus <regimen> or its equivalent not considered hematopoietic stem cell transplant hsct candidates based on investigator s discretion
subject has history of hypersensitivity reaction to temozolomide or a history of hypersensitivity to dacarbazine <regimen>
such subjects may receive therapy with trametinib in combination with dabrafenib in case of an adverse event related to a previous braf or mek inhibitor other than trametinib or dabrafenib and without cross reaction anticipated or if clinically indicated according to investigator judgement prior treatment except trametinib and dabrafenib should have been stopped for a period of 5 half lives or 28 days whichever is shorter before starting treatment of this study <regimen> if the subject has benefited from a treatment with a braf inhibitor without progression but cannot receive it anymore due to tolerability reason
if a participant has received subsequent anticancer therapy salvage therapy the participant must have a wash out period defined as 2 weeks or 5 pharmacokinetic half lives of the treatment whichever is longer before the planned start date of <regimen>
negative serum human chorionic gonadotropin hcg pregnancy test within 72 hours of day 1 of treatment with <regimen> in women of child bearing potential
vincristine <regimen> chemotherapy
treated by rituximab <regimen> or rituximab mini <regimen>
no contraindication to modified folfox6 or <regimen> combination chemotherapy
serious coexisting medical condition or active infection which would compromise the ability to deliver standard r <regimen> chemotherapy
adenocarcinoma of the breast planned to receive a minimum of 2 cycles of <regimen>
patient administering <regimen> 6 folinic acid 400 mg m2 1 day oxaliplatin 85 mg m2 1 day 5 fluorouracil 400 mg m2 bolus 2400 mg m2 continuous infusion 48 hours
previous enrollment in the present study female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or180 days after the last dose of durvalumab tremelimumab combination therapy received more than 2 prior systemic chemotherapy regimens including adjuvant systemic chemotherapy following definitive chemoradiation outback chemotherapy concurrent chemotherapy with prior radiation treatment is not to be counted prior treatment with an anti ctla 4 including tremelimumab pd 1 or pd l1 inhibitor including durvalumab
tumor response after 8th cycles of <regimen> ctx sd stable disease
patients who had investigator assessed progression on an oxaliplatin containing regimen such as <regimen> or <regimen> are not eligible for the trial
patient must have progressed or be refractory to prior anthracycline containing chemotherapy egr <regimen> <regimen> r etc
planned to start trastuzumab based neo adjuvant therapy <regimen> or <regimen> or dose dense <regimen> or docetaxel cyclophosphamide trastuzumab or docetaxel carboplatin trastuzumab or weekly paclitaxel with trastuzumab
previous radiotherapy of the brain or chemotherapy with <regimen> or tmz
qualified for an application of <regimen> cetuximab treatment
have not received anti cancer therapy for at least 2 weeks prior to study entry with the exception of low dose ara c <regimen> given as subcutaneous injections no less than 15 days prior hydroxyurea or anagrelide no less than 24 hours prior tki no less than 5 days prior and interferon no less than 2 weeks prior have an ecog performance of 0 2
<regimen> cycle delay is also permitted
subjects with a condition requiring systemic treatment with systemic corticosteroids equivalent of 10mg day of prednisone patients may receive steroid therapy up to 10 days prior to starting <regimen> to control lymphoma related symptoms
this may include a combination regimen including lenalidomide these regimens will include dexamethasone cyclophosphamide etoposide cisplatin <regimen> velcade with doxil cytoxan and or lenalidomide patients who have thrombocytopenia cit from lenalidomide or from radiation therapy alone will not be allowed
subjects must not have had prior rt chemotherapy including <regimen> immunotherapy or therapy with a biologic agent or hormonal therapy
histologically diagnosed non hodgkin s lymphoma patients treated by <regimen> regimen or r rituximab <regimen> regimen at 215 days interval
severe illness or organ dysfunction involving the heart kidney liver or other organ system egactive infection clinically relevant impairment of cardiac function severe heart failure cardiac insufficiency unstable angina pectoris or history of recent myocardial infarction which in the opinion of the investigator precludes treatment with <regimen>
planned treatment with r <regimen> chemotherapy
recovery from <regimen> toxicities
non response to the maximum tolerated dose of <regimen> for at least 3 months
in patients receiving <regimen> oxaliplatin is sometimes discontinued due to toxicity or as part of maintenance therapy strategy
any other active infection viral fungal or bacterial requiring systemic therapy history of allogeneic tissue solid organ transplant diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of <regimen> treatment
patients foreseen for chemotherapy with <regimen> in second or further line treatment
subject elected not to undergo treatment with <regimen>
1 histologically proven and unresectable locally advanced recurrent or metastatic squamous cell anal carcinoma presence of a target lesion on ct scan assessed by recist v1 1 criteria patient eligible to the <regimen> regimen 6
presence of abnormal or clinically significant cardiac disease such as acute myocardial infarction or unstable angina within 6 months prior to initiation of treatment with lr <regimen> grade iii or iv heart failure uncontrolled hypertension or history of poor compliance with antihypertensive treatment uncontrolled treated arrhythmias except with the exception of extra systoles or minor conduction abnormalities
the patient will have to have received at least one cycle of bevacizumab in combination with <regimen> bevacizumab as part of the first line treatment
person who is confirmed as colorectal cancer through histological and image diagnosis and scheduled for adjuvant or palliative therapy with <regimen> 6 regimen
progressive disease despite at least 1 cycle of <regimen> like or any anthracycline base chemotherapy or at least 1 cycle part a or a and b of <regimen> like chemotherapy
planned to start either fec d ac d dose dense ac t <regimen> or tc chemotherapy in the adjuvant or neoadjuvant setting
patients enrolling onto arm a gemcitabine and nab paclitaxel or arm b <regimen> are allowed to have up to two prior lines of systemic therapy with adjuvant therapy counted as one line of therapy as long as disease recurrence occurred 6 months of last dose of therapy
6 to 8 cycles r <regimen> like total of 8 x rituximab
patients curatively treated and disease free for at least 5 years will be discussed with the sponsor before inclusion squamous gastric cancer concurrent chronic systemic immune therapy chemotherapy or hormone therapy not indicated in the study protocol previous therapy with paclitaxel or <regimen> current treatment with any anti cancer therapy 2 weeks prior to study treatment start unless rapidly progressing disease is measured concurrent treatment with any other anti cancer therapy previous exposure to a vegf or vegfr inhibitor or any antiangiogenic agent or prior enrolment in this study patient has undergone major surgery within 28 days prior to first dose of protocol therapy or minor surgery subcutaneous venous access device placement within 7 days prior to first dose of protocol therapy
phase 2 only subjects on <regimen> arm must have documented cr pr or sd for 12 weeks prior to disease progression in order to cross over to combination therapy arm
contraindication to any drug contained in the r <regimen> rituximab cyclophosphamide doxorubicin vincristine prednisone
significant prior doxorubicin 240 mg m2 or anthracycline exposure that would preclude the safe administration of <regimen> chemotherapy as described in the protocol
histological confirmation of relapsed refractory diffuse large b cell lymphoma after prior rituximab and anthracycline containing systemic treatment regimen such as r <regimen> rituximab cyclophosphamide doxorubicin vincristine and prednisone <regimen> rituximab etoposide phosphate prednisone vincristine sulfate cyclophosphamide doxorubicin hydrochloride r <regimen> rituximab cyclophosphamide vincristine sulfate doxorubicin hydrochloride dexamethasone etc
investigator determined assessment of disease progression after treatment with <regimen> or investigator determined assessment of current stable disease following completion of at least 4 cycles but no more than 8 cycles of <regimen> have resolution of all previous treatment related toxicities to grade 1 severity or lower except for stable sensory neuropathy less than or equal to grade 2 or alopecia
capecitabine and oxaliplatin <regimen>
a non gemcitabine based regimen including but not limited to leucovorin calcium fluorouracil irinotecan hydrochloride and oxaliplatin <regimen> or any combination of components therein
bone marrow cellularity greater than 15 no evidence of myelodysplasia morphologically and no evidence of involvement with lymphoma either at the pre r <regimen> marrow or on repeat assessment pre zevalin
treatment with drugs other than <regimen>
subject must be receiving a stable dose of clb and vpa administered twice daily to be eligible for dose <regimen> and 2 or subject must be receiving a stable dose of clb vpa and stp administered twice daily to be eligible for dose regimen 3 cohort 1 only key
at least 6 months since prior anthracycline therapy eg cyclophosphamide doxorubicin vincristine and prednisone <regimen>
previously untreated nhl suitable for <regimen> r <regimen> treatment
if the patients could well tolerate the adjuvant chemotherapy it is recommended that patients can obtain maintenance treatment of apatinib after postoprative adjuvant chemotherapy of eight cycles of <regimen>
have received a second line chemotherapy after progressing on or not tolerating treatment with <regimen> as a first line
women should not breastfeed while taking study treatment and for 4 weeks after the last dose of napabucasin or while undergoing treatment with <regimen> and for 180 days after the last dose of <regimen>
leucovorin fluorouracil and irinotecan <regimen>
prior treatment with 5 azacytidine followed immediately by <regimen> and mitoxantrone as proposed in this study note
induction chemotherapy with r <regimen> should also be completed at the participating centre but exceptions can be made according to the discretion of the centre s primary investigator
2 1 2 1 patients who have relapsed from their initial adriamycin bleomycin vinblastine dacarbazine <regimen> or similar standard treatment regimen and have not received any other chemotherapy or salvage systemic treatment 2 1 2 2 patients that have received prior radioimmunotherapy 2 1 2
chemotherapy with <regimen> <regimen> <regimen> or capecitabine the current standard treatment it can be modified in the future in the two groups if the standard is modified
prior <regimen> or <regimen> therapy and prior bone marrow or pbpc transplant
patients with advanced stage chl treated with <regimen> at the british columbia cancer agency bcca
contraindication to receive any of the individual components of <regimen> rituximab or obinutuzumab
treatment with <regimen> within 3 months or rituximab combination therapies example with bendamustine fludarabine ibrutinib or cytotoxic drugs within 6 months prior to enrollment
diagnosis of hodgkin s lymphoma failing or relapsing after first line chemotherapy <regimen> avbd <regimen>
received <regimen> rituximab or equivalent regimen
fresh tumor tissue must be provided for all subjects for biomarker analysis before within 14 days prior to treatment start and during on day 10 of the <regimen> and the last day of the treatment with pazopanib day 70 treatment with investigational product asservation in rnalater for kryo asservation and for cell cultures
exclusion criteria reduced intensity conditioning regimen for both <regimen> <regimen> regimens
no concurrent polifeprosan 20 with carmustine implant <regimen>
patients must have recurrent or refractory intermediate grade or high grade non burkitt s non hodgkin s lymphoma nhl or hodgkin s disease and be scheduled for a minimum of 2 cycles of <regimen> dexamethasone high dose cytarabine and cisplatin chemotherapy
not pretreated but scheduled to be treated with <regimen> cyclophosphamide hydroxydaunomycin oncovin and prednisolone
no prior chemotherapy for the brain tumor except polifeprosan 20 with carmustine implant <regimen>
patients will only be eligible if their last line of therapy prior to enrolling onto the study was <regimen> and bevacizumab received no more than 6 months prior to enrolling in this study they should have been treated with <regimen> plus bevacizumab until disease progression is radiographically documented
patient naive to any chemotherapy treatment re ceiving a 1st chemotherapy line of <regimen> rcop vtd vd or mpt type from the adult hematology department
all the patients have to be treated with the same chemotherapy protocol <regimen> with or without rituximab to avoid confounding factors
leucovorin fluorouracil and oxaliplatin <regimen>
stage i or ii of primary breast dlbcl treated with r <regimen>
histologically confirmed diffuse large b cell lymphoma treated with r <regimen> rituximab cyclophosphamide adriamycin vincristine prednisolone chemotherapy 2
two prior chemotherapy regimens allowed provided 1 of the 2 regimens was <regimen> as second line therapy
histologically or cytologically proven solid tumour for which cpt 11 given by the <regimen> regimen is indicated and prescribed by the attending physician
one prior systemic chemotherapy and any number of immunotherapies or vaccine therapies are allowed prior treatment with <regimen> infusion or perfusion or chemoembolization of liver metastasis is allowed prior treatment with radiation therapy is allowed but not more than 3000 cgy to fields including substantial marrow patients are not required to have had prior therapy
the subject intends to undergo treatment with the <regimen> at the time of this surgery prior intracranial gamma knife stereotactic radiosurgery or other focal high dose radiotherapy is not allowed severe pulmonary cardiac or other systemic disease specifically
more than stable disease after 6 cycle 1st line of <regimen> chemotherapy or non complete response non progressive disease in cases of non measurable disease before <regimen> chemotherapy
those patients who enroll just after completing bevacizumab plus <regimen> or <regimen>
exclusion criteria investigator predicted life expectancy of less than two months investigator predicted inability to tolerate <regimen> treatment adverse effects for less than two months prior anthracycline treatment with a cumulative dose exceeding 450 mg m2 calculated based on doxorubicin equivalents
subjects with histologically or cytologically confirmed malignancy that is meta static or unresectable and for which standard curative measures or other therapy that may provide clinical benefit do not exist or are no longer effective or for whom treatment with <regimen> is a viable option
not eligible for anthracycline based first line chemotherapy eg r <regimen>
these patients would be enrolled in a high dose protocol using carmustine etoposide cytarabine and cytoxan <regimen> with autologous hematopoietic rescue
140 90 mmhg on more than 2 antihypertensive medications myocardial infarction severe angina or unstable angina within 12 weeks prior to start of cycle 1 of <regimen> bevacizumab cetuximab administration history of serious ventricular arrhythmia ie ventricular tachycardia or ventricular fibrillation
patients must have been detected with an activating egfr mutation at baseline and must have yet progressed on erlotinib gefitinib or <regimen> in daily dose of 150 mg 250 mg or 40 mg respectively
previously untreated dlbcl patients who are suitable for receiving r <regimen> chemotherapy
for example a patient who started treatment with rituximab bendamustine and was then switched to r <regimen> due to insufficient response or excessive toxicity would be counted as having received 2 regimens however r <regimen> alternating with r <regimen> as a planned induction regimen would count as one regimen
for advanced stage iii iv hodgkin disease patients must have failed an adriamycin containing regimen <regimen> or an alternative non cross resistant regimen egmopp
have reached a cr or pr after first line treatment with at least 6 cycles of r <regimen> 14 regimens and up to 8 cycles of r chop21
inclusion criteria for patients undergoing r <regimen>
initial laboratory data should be compatible with the administration of standard doses of <regimen> chemotherapy
known hypersensitivity to srl or its derivatives macrolide antibiotics corticosteroids <regimen> or mmf
allo hct patients any allogeneic transplant regimen with planned gvhd prophylaxis containing generic iv mycophenolate mofetil mmf and tacrolimus <regimen>
current uveitis therapy must conform to one of the following <regimen> at a dose of 10 mg day or equivalent for 2 weeks prior to randomization have received 2 injections of corticosteroid intravitreal or periocular for control of disease within the past 8 months but not within 2 weeks of randomization subjects may also be receiving systemic corticosteroid therapy receiving monotherapy with azathioprine mycophenolate mofetil mycophenolic acid or methotrexate for at least 2 weeks prior to randomization receiving prednisone in addition to one immunomodulatory agent from among cyclosporine tacrolimus azathioprine mycophenolate mofetil mycophenolic acid and methotrexate for at least 2 weeks prior to randomization subjects for whom corticosteroid therapy systemic or local is medically inappropriate or who refuse corticosteroid therapy
received 3 previous anticancer regimens prior to enrollment received prior r <regimen> therapy
disease evaluation with proven sd pr or cr according to recist after 8 cycles of <regimen> or <regimen>
<regimen> fr pcr fludarabine or alemtuzumab based regimen or bendamustine based regimen prior to study enrollment
patients must have received initial cisplatin based combination therapy such as bleomycin etoposide and cisplatin bep etoposide and cisplatin ep vp 16 plus ifosfamide plus cisplatin vip or similar regimens and demonstrated progression following the administration of at least one salvage regimen for advanced germ cell neoplasm such as high dose chemotherapy paclitaxel ifosfamide cisplatin tip or vinblastine ifosfamide and cisplatin <regimen>
patient with a history of classical hl relapsed refractory which received <regimen> regimen as induction therapy before high dose chemotherapy with ahsct
patients who are or plan to be immunized with live virus vaccine within 28 days or within 5 half lives of the drug before enrollment patients who underwent or plan to undergo major surgery within 28 days before enrollment or patients whose surgical wounds have not healed patients who are receiving continuous corticosteroid treatment with 30 mg day prednisone or equivalent dose of corticosteroids for 10 days of continuous treatment have a history of gastrointestinal perforation and or fistula within 6 months before enrollment known to be allergic to monoclonal antibody mab therapy or rituximab or patients with known sensitivity or allergy to murine products patients who have contraindications to any component of the <regimen> regimen have previously received treatment for dlbcl including chemotherapy immunotherapy local radiotherapy for lymphoma surgical treatment except for tumor or pathologic biopsy and surgical resection not for lymphoma and any monoclonal antibody therapy within 3 months prior to enrollment have previously received cytotoxic drugs or anti cd20 monoclonal antibody therapy for other diseases such as rheumatoid arthritis have a history of other malignancies that may affect study protocol compliance or result analysis also suffering from severe non malignant diseases that can affect study protocol compliance such as severe cardiovascular diseases uncontrolled diabetes and hypertension peripheral nervous system or central nervous system diseases known to have uncontrollable active infectious diseases or any major infection events other than neoplastic fever requiring intravenous antibiotic treatment or hospitalization within four weeks prior to enrollment
newly diagnosed de novo dlbcl or primary mediastinal b cell lymphoma that will be treated with an anthracycline containing regimen rituximab cyclophosphamide doxorubicin hydrochloride prednisone r <regimen> or equivalent
progressing or relapsed following prior treatment including but not limited to rituximab <regimen> chemotherapy regimen
imatinib transient dose adjustments due to adverse event aes are allowed with a maximum of 2 weeks interruption of treatment with imatinib cumulative within the 3 month period before randomization <regimen> must have been started within 6 months of cp cml diagnosis ph bcr abl detection
a patient enrolled in another clinical trial may also enroll in this study if the other trial has an r <regimen> treatment arm and the patient is randomized to the r <regimen> only arm
subject has mf with evidence of persistent disease despite <regimen> treatment consisting of persistent or worsening disease related symptoms including but not limited to fatigue pruritus night sweats early satiety and other symptoms as determined by a mpn saf tss score of 20 points and documented splenomegaly of at least 5 cm below the costal margin as measured on inspiration by physical exam
male or female patients of reproductive potential who are not willing to employ highly effective methods of contraception from screening to 180 days after receipt of the final dose of durvalumab and tremelimumab in combination or 90 days after the last dose of <regimen> or vinorelbine
cr relapsed within 1 year following completion of front line <regimen> or <regimen> relapsed at any time following front line <regimen> <regimen> or other hybrid eligible
received 6 cycles 3 months 12 weeks of first line therapy with <regimen> or <regimen> plus bevacizumab for metastatic crc patients
failure requiring hemo or peritoneal dialysis dehydration according to nci ctc v 4 0 grade 1 substance abuse medical psychological or social conditions that may interfere with the patient s participation in the study or evaluation of the study results known hypersensitivity to any of the study drugs study drug classes or excipients in the formulation interstitial lung disease with ongoing signs and symptoms at the time of informed consent inability to swallow oral medications any malabsorption condition unresolved toxicity higher than ctcae v 4 0 grade 1 attributed to any prior therapy procedure excluding alopecia and oxaliplatin induced neurotoxicity which must be grade 2 patients unable or unwilling to discontinue and substitute if necessary use of prohibited drugs for at least 30 days prior to day 1 of <regimen> initiation see appendix b for list of prohibited drugs
adjuvant therapy with <regimen> or 5 fu capecitabine
previously untreated hodgkin s disease patients who are scheduled to receive standard <regimen> chemo
as an example a patient who is begun on <regimen> or <regimen> capecitabine with oxaliplatin with or without bevacizumab whose oxaliplatin is held for neurotoxicity and who is switched to <regimen> or capecitabine with bevacizumab would be considered to have had one prior therapy
no prior polifeprosan 20 with carmustine implant <regimen>
pulmonary function test pft demonstrating an adjusted diffusion capacity of least 50 predicted value for hemoglobin concentration myeloablative <regimen> reduced intensity regimen 3
histologically confirmed stage iv colorectal adenocarcinoma previously treated with <regimen> and <regimen> and bevacizumab receipt of cetuximab or panitumumab is not required and has shown progression or intolerant of both oxaliplatin and irinotecanbased regimens baseline tumor assessments must be done within 28 days of starting treatment
exclusion criteria serious intercurrent medical illnesses which would interfere with the ability of the patient to carry out the treatment program pregnant or breastfeeding women patients who have uncontrolled active infection patients who have received another investigational product within the longer of 14 days or 5 half lives of the previous product any history of adverse reaction or hypersensitivity to <regimen> part
prior therapy with 5 azacytidine or decitabine or <regimen> or mitoxantrone would be allowed in patients with relapsed refractory disease unless the prior therapy was identical to the schema schedule proposed in this study
patients who had failed first line treatment with either <regimen> capecitabine combined with oxaliplatin or <regimen> 5 fluorouracil leucovorin with oxaliplatin
treatment planned with adriamycin bleamycin vinblastine dacarbazine <regimen> or bleomycin etoposide
previously participated in another <regimen> driving simulator study
previous treatment up to one cycle of standard pretreatment with cop <regimen> or steroids permitted and latter mandatory to decrease tumor burden and or improve performance status
planned local low dose radiation therapy <regimen> at the department of radiation oncology universittsklinikum erlangen
previously received 1 or more appropriate systemic therapies eg non anthracycline based regimens such as l asparaginase based therapy for cohort 1 and combination chemotherapy eg <regimen> epoch or similar therapy for cohort radiation therapy alone would not be acceptable previous therapy
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy
no prior chemotherapy for hodgkin s disease except single course of <regimen> doxorubicin bleomycin vinblastine and dacarbazine within 35 days of study endocrine therapy
such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine if appropriate eg <regimen> and <regimen> or their variants
has the subject elected not to undergo treatment with the <regimen>
patients received six months of systemic chemotherapy currently the <regimen> 4 regimen which could be modified if the standard is modified
inclusion criteria male or female 18 years of age at time of consent has an eastern cooperative oncology group ecog performance status of 0 1 or 2 has histologically confirmed diffuse large b cell lymphoma dlbcl primary mediastinal b cell lymphoma pmbcl marginal zone lymphoma mzl mantle cell lymphoma mcl or histologically and or cytologically confirmed advanced or metastatic solid tumor and have relapsed or refractory disease following at least two lines of prior standard therapy including alkylator anthracycline unless anthracycline based chemotherapy is contraindicated anti cd20 based therapy r <regimen> rituximab doxorubicin cyclophosphamide vincristine and prednisolone or prednisone or equivalent and must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation asct as defined by meeting at least one of the following criteria relapsed following or refractory to
intended initial treatment to include 2 cycles of r <regimen> <regimen> or r <regimen> using standard doses and schedule
prior polifeprosan 20 with carmustine implant <regimen>
scheduled to receive first line chemotherapy <regimen> bevacizumab or <regimen> bevacizumab for metastatic disease
major concurrent illness which could worsen following treatment with anti <regimen>
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control as described in the protocol from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with ibrutinib <regimen>
hodgkin s or non hodgkin s lymphoma failed at least 1 conventional second or third generation regimen eg <regimen>
subjects must have progressed after receiving at least one cycle of <regimen> or tmz containing regimen
mm only prior treatment with dna damaging agents or cytotoxic chemotherapy including carboplatin cisplatin fotemustine paclitaxel vincristine tmz and <regimen>
the effects of bcnu the active ingredient in the <regimen> with concomitant temozolomide on the developing human fetus are unknown
the target population is patients with metastatic colorectal adenocarcinoma who are sufficiently robust to undergo at least 3 cycles of oxaliplatin based chemotherapy <regimen> or <regimen>
patients who have received prior chemotherapy other than first line <regimen> patients
60 years due to the fact that <regimen> r is not studied enough in younger patients and is not considered standard of care
eligible for <regimen> <regimen> <regimen> and bevacizumab treatment in accordance with local standards of care and pharmaceutical benefits scheme additional inclusion criteria for participants with primary tumor in situ
use of any first line treatment with a chemotherapy regimen other than <regimen> <regimen> or <regimen> each with or without bevacizumab
subject progressed during or within 3 months of completion of a planned course of first line therapy with rituximab cyclophosphamide hydroxydaunomycin vincristine oncovin prednisone r <regimen> or an equivalent regimen
patient has a known hypersensitivity to prograf <regimen> hco 60 cellcept mmf zenapax or corticosteroids
that according to the investigator does not allow the administration of 2 courses of <regimen> ivac
in part ii subjects still have to undergo at least 2 planned cycles with <regimen>
completion of a full course of first line immunochemotherapy including rituximab or completion of 4 cycles of first line immunochemotherapy including rituximab if intolerant egwhich include but are not limited to r <regimen> <regimen>
no more than 8 weeks between 1st line treatment with <regimen> avastin and 2nd line treatment with <regimen> or <regimen> avastin
history of known hypersensitivity to s cerevisiae bevacizumab or any component of <regimen> or <regimen>
be previously chemotherapy treated all patients may have received up to two prior lines of chemotherapy excludes systemic therapy for recurrent advanced disease as long as one of those regimens was platinum based it is anticipated that patients would have been previously treated with <regimen> or gc or variations of these standard frontline regimens
patients who have received chemotherapy for pancreatic cancer other than up to 4 cycles of <regimen>
subjects enrolled on the combination therapy phase must not meet the above exclusion criteria and must be eligible to receive paclitaxel or <regimen> per most current prescribing information or at the discretion of the investigator
her2 targeted monoclonal antibody therapy is defined as either <regimen> or trastuzumab and pertuzumab combination therapy administered per standard of care
past hypersensitivity reaction to temozolomide or <regimen>
previous intolerance to either mmf <regimen> scr 200umol l informed consent unavailable
prior <regimen> treatment but have not been appropriate for safety reasons
known hypersensitivity reaction to temozolomide or any of its components or dacarbazine <regimen> if enrolled on arm 1 or irinotecan or any of its components if enrolled on arm 2
prior polifeprosan 20 with carmustine implant <regimen> allowed
former second line treatment of the colorectal cancer without <regimen> irinotecan or an anti egfr substance with data available for the substances administered duration of treatment and response within the context of the second line treatment
second line oxaliplatin based <regimen> <regimen> or <regimen> bevacizumab containing therapy
general status that does not allow the administration of 8 courses of <regimen> according to the investigator
pbpcs should have been collected after the first or the second <regimen> cycle age 18 years 7
be actively receiving <regimen> on the previous study within 14 days of study entry and demonstrating clinical benefit complete response cr partial response pr stable disease sd of continued use or
stage ii iii or iv patients who received <regimen> or <regimen> induction chemotherapy for 6 cycles confirmed response as more than pr or pr after induction therapy and who are ineligible for transplantation
patients enrolling onto arm b <regimen> are allowed to have prior gemcitabine with nab paclitaxel in combination with bbi608 in the metastatic setting
all cases have been diagnosed with colorectal cancer by pathology patients who received no chemotherapy before should receive oxaliplatin based chemotherapy <regimen> folfox6 <regimen> patients of 18 70 years old have no serious heart liver kidney and hematopoietic disfunction life expectancy of over 3 months and kps more than 60 patients with no positive sign in neurological examination and no drug allergy history or diabetes volunteered to participate and signed informed consent patients can not receive radiotherapy acupuncture and moxibustion or other treatment during the experiment
received <regimen> within 6 weeks before starting regorafenib
pre or post operative chemoradiation and at least 3 months of adjuvant systemic chemotherapy equivalent to 6 cycles of leucovorin calcium fluorouracil and oxaliplatin <regimen> or infusional fluorouracil 5fu
refractory to or intolerant of standard systemic therapy including having received two or more standard available therapies known to prolong survival for which s he was eligible including <regimen> or <regimen> with or without bevacizumab aflibercept cetuximab or panitumumab
the only exception is the emergency use of a short course of corticosteroids equivalent of dexamethasone 40 milligram per day for a maximum of 4 days before <regimen>
female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
cisplatin vinblastine dacarbazine <regimen> interferon and interleukin 2
paraffin block of the lesions available for immunohistochemical analysis candidate for <regimen> salvage therapy evidence of at least one lesion with a diameter of 1 5 cm age of over 20 years eastern cooperative oncology group performance status ecog less than or equal to 2
patients who had previously received treatment with gemcitabine based chemotherapy failed and received fluorouracil based chemotherapy such as <regimen> and had received or not received radiotherapy and failed treatment 2
absolute neutrophil count 1 5 x 109 l unless due to bone marrow involvement with lymphoma or due to initiation of r <regimen> chemotherapy
have completed curative treatment for breast cancer 4 have not experienced a cancer recurrence and 5 report a clinically significant level of <regimen> as assessed with the fear of cancer recurrence inventory short form 13
scheduled to receive adjuvant paclitaxel carboplatin for ovarian or endometrial cancer or <regimen> for colorectal cancer
patient has received any prior cytotoxic chemotherapy for pancreatic cancer with the exception of patients who progressed on or were intolerant of 1st line <regimen> prior
patients 18 years of age with a hematologic malignancy other than aplastic anemia or primary myelofibrosis scheduled to undergo ric allogeneic sct with a peripheral blood stem cell graft from an unrelated donor using <regimen> conditioning and <regimen> mtx gvhd prophylaxis
in the setting of metastatic disease requiring local palliation only radiosensitizing doses of 5 fu or <regimen> are permitted
at least 5 percent of each patient s peripheral blood lymph node pulmonary or dermal malignant cells must react with the anti <regimen> mab as determined by immunofluorescent staining or alternatively the serum soluble interleukin 2 il 2 receptor levels must be greater than 1 000 units ml normal geometric mean 235 with a 95 confidence interval of 112 to 502 units ml
patients with badly chemotherapy complications who can finish the whole <regimen> treatment course
failure of at least one prior chemotherapy regimen of <regimen> and or temozolomide with without interleukin 2 il 2
key inclusion criteria males and females at least 18 years of age diagnosis of high risk stage i ii or iiia breast cancer suitable for adjuvant <regimen> chemotherapy as based on investigator judgment candidates for <regimen> chemotherapy and no prior treatment with anthracyclines
allogeneic hematopoietic stem cell transplantation allo hsct eligible meeting institutional criteria participants planned medical care should include acute graft versus host disease agvhd prophylaxis with a combination of calcineurin inhibitor cni cyclosporine cys or tacrolimus <regimen> and methotrexate mtx or cni and mycophenolate mofetil mmf with the exception of antithymocyte globulin atg antithymocyte globulin fresenius atg f or thymoglobulin all other therapies approved or investigational for graft versus host disease gvhd prophylaxis are excluded
inclusion in the target population scheduled to receive at least 3 consecutive cycles of the same regimen of <regimen> or <regimen> without monoclonal antibody
may not have had previous treatment with a dacarbazine <regimen> or temozolomide based chemotherapy regimen
patients with cancers colorectal breast who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy mainly <regimen> regimen
patients who have a treatment plan based on <regimen> anti egfr or <regimen> anti egfr as first line treatment of mcrc
based chemotherapeutic regimen containing carboplatin cisplatin or another organoplatinum compound must have had at least 1 prior paclitaxel based chemotherapeutic <regimen> or 2 prior chemotherapy regimens containing platinum and paclitaxel allowed recovered from toxic effects
adult age 18 and older who has decision making authority for <regimen> patient who has been referred to the pediatric advanced care team pact for palliative care services and with a child ren age 6 11 years who is a sibling of the patient
live vaccine within 30 days prior to the first dose of <regimen> treatment or during study treatment
chemotherapy treatments planned r <regimen> but not started
patients who discontinue prior ipilimumab nivolumab or <regimen> for toxicity are excluded
patients who have required toxicity related dose reductions of no less than 50 of the original dose of infusional 5 fu and or irinotecan during the administration of <regimen> bevacizumab
patients with de novo aggressive b cell lymphoma must have relapsed or progressed or have biopsy proven refractory disease after 1 prior line of therapy r <regimen> chemotherapy or equivalent patients with histological transformation from low grade lymphoma may have had up to 3 prior treatment regimens
seen for follow up oncology care at <regimen> or penn
concurrent use of bevacizumab or cetuximab in combination with <regimen> as part of a clinical trial or clinical practice are allowed
prior treatment with <regimen> adjuvant
patients must either receive 4 cycles of anthracycline for a total dose of 240 mg m2 or six cycles of <regimen> for a total dose of 300 mg m2 or trastuzumab
prior therapy allowed but no prior therapy with nab paclitaxel paclitaxel temozolomide <regimen> or bevacizumab
first line treatment with an irinotecan based regimen eg <regimen>
patients with recurrent metastatic liver lesions from colorectal cancer who progressed on either <regimen> or <regimen>
prior chemotherapy with <regimen>
untreated for metastatic colorectal cancer or progression on any first line 5 fu containing regimen such as <regimen> or <regimen>
scheduled to begin fluorouracil leucovorin calcium oxaliplatin <regimen> or folinic acid fluorouracil irinotecan <regimen> based chemotherapy for the advanced disease
patient must not have received prior temozolomide dacarbazine <regimen> or capecitabine or 5 fu fluorouracil therapy
exclusion criteria received chemotherapy within last 3 month prior to screening or expected to receive any chemotherapy other than <regimen> and or immunotherapy between screening and 30 days after last planned study drug administration any clinically significant findings on history or examination that in the opinion of the investigator would preclude administration of <regimen> chemotherapy in the full dose including abnormal liver function inadequate cardiac function or clinically significant cardiac disease neuropathy or other disease prior bone marrow or peripheral blood hematopoietic stem cell transplant
a history of known human immunodeficiency virus hiv hepatitis b virus hbv or hepatitis c virus hcv infection history or clinical evidence of brain metastases or leptomeningeal disease any other malignancy from which the patient has been disease free for less than 5 years with the exception of adequately treated and cured basal or squamous cell skin cancer superficial bladder cancer or carcinoma in situ of the cervix treatment with <regimen> within 6 months before start of study treatment with ipilimumab within 6 months before start of study hypersensitivity to <regimen> concomitant use of drugs known to alter cardiac conduction chronic use of corticosteroids used in the management of cancer or non cancer related illness
failed <regimen> combination chemotherapy at any time point
patients must not have received more than one other systemic or itv adjuvant chemotherapy regimen in addition to temozolomide prior to enrollment not including intracavitary <regimen> placement
histological or cytological documentation of adenocarcinoma of the colon or rectum and patient scheduled to begin <regimen> for treatment of their metastatic disease patients taking statins at the time of enrollment are permitted
patients are not considered to have a currently active malignancy if they have tki258 <regimen> phase 1 protocol version 3 3 dated 30 november 2011 1 4 completed therapy and are considered to have a less than 30 risk of relapse
cd25 all stages of <regimen> expressing adult t cell leukemia except smoldering are eligible patients with chronic lymphomatous or acute adult t cell leukemia atl are eligible
because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with <regimen> breastfeeding should be discontinued if the mother is treated with these agents
acute lymphoid leukemia patients receiving <regimen> r cyclophosphamide vincristine doxorubicin dexamethasone methotrexate cytarabine rituximab
to 2 0 x normal myeloablative <regimen> reduced intensity regimen 3
to have received first line treatment with bevacizumab in combination with chemotherapy with the three drugs 5fu leucovorin lv irinotecan and oxaliplatin <regimen> and
dlbcl patients that will be eligible in front line treatment for a combination of anthracycline based chemotherapy plus anti cd20 monoclonal antibody rituximab r <regimen> 14 r <regimen> 21 r mini <regimen> r <regimen> <regimen> patients
<regimen> refractory patients with crc enrolling on the <regimen> study arm must have failed treatment with one <regimen> with or without bevacizumab regimen for unresectable or metastatic disease
r <regimen> chemotherapy
inclusion criteria patients enrolled in the big 1 trial at diagnosis patients achieving first cr crp cri after induction or salvage therapy within 15 days before r4 vos favorable or intermediate risk aml patients as stratified with big 1 prognostic classification patients randomized to r2 <regimen> arm intermediate dose cytarabine 5
for patients who are her2 positive and will be treated on the trastuzumab <regimen> cohort left ventricular function 50
patients with other cancers excluding nonmelanomatous skin cancers or carcinoma in situ <regimen> placement at the time of surgery tab tab
relapse after initial radiotherapy with complete response longer than 1 year since initial therapy and subsequent failure on <regimen> and or <regimen> or hybrid
the post <regimen> response evaluation must include a ct scan of the chest abdomen and pelvis gallium scan is optional for patients who have palpable cervical lymphadenopathy a ct scan of the neck must be performed following <regimen> chemotherapy
<regimen> r chemotherapy
because no dosing or adverse event data are currently available on the use of midostaurin in combination with atra and <regimen> in patients 18 years of age children are excluded from this study but will be eligible for future pediatric phase 2 combination trials
bevacizumab or <regimen> patients may have received a maximum of 12 cycles of <regimen> or <regimen>
in the opinion of their treating oncology investigator are candidates for at least 4 cycles of chemotherapy with <regimen> docetaxel doxorubicin cyclophosphamide
for example a patient who started treatment with rituximab bendamustine and was then switched to rituximab r cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone <regimen> due to insufficient response or excessive toxicity would be counted as having received 2 regimens however r <regimen> alternating with r dexamethasone high dose cytarabine and cisplatin <regimen> as a planned induction regimen would count as one regimen
patients must have failed front line standard anthracycline containing regimen such as <regimen> <regimen> or <regimen>
it will be included in the study newborns nb hospitalized in the nursery and patients aged 18 or over male and female conscious and oriented presenting glasgow coma scale of 15 hospitalized at the clinical hospital of <regimen> who will not be discharged from it for at around the 3 following days
patients must have received at least one prior standard cytotoxic regimen such as <regimen> or epoch or b
planned adjuvant chemotherapy including an anthracycline and taxane using either dose dense or docetaxel doxorubicin hydrochloride and cyclophosphamide <regimen> regimens with or without trastuzumab herceptin for 4 months docetaxel and cyclophosphamide tc with or without trastuzumab for 3 months doxorubicin hydrochloride and cyclophosphamide ac for 3 months or doxorubicin hydrochloride carboplatin and trastuzumab tch for 4 months trastuzumab may be given for 1 year and is not considered chemotherapy for the purpose of this study
patient planned to receive one of the following chemotherapy protocols including bortezomib velcade vmp velcade melphalan prednisone vcd velcade cyclophosphamide dexamethasone <regimen> velcade dexamethasone vrd velcade revlimid dexamet
<regimen> within 14 days prior to starting combination therapy is allowed for crossover subjects in cohort a
use of investigational drugs within 3 weeks of signing consent or foreseen use during the study use of chemotherapy trastuzumab or pertuzumab within the past 3 weeks use of antibiotics within the past 7 days up to 2 prophylactic doses of antibiotics for procedures including but not limited to port placement is permitted any type of ostomy total colectomy fecal incontinence ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study active systemic infection requiring ongoing intervention including but not limited to oral and intravenous antibiotics anti fungals anti parasites anti virals abdominal or pelvic surgery without recovery of bowel function inadequate organ function for starting thp or <regimen> which may include the following laboratory results within 28 days prior to signing
former first line treatment of the metastatic colorectal cancer with <regimen> and cetuximab data available for the duration of treatment and the response within the context of first line treatment
patient must have received 1 prior course of chemotherapy <regimen> regimen for metastatic disease
5 fluorouracil these include combinations such as fluorouracil oxaliplatin and leucovorin calcium <regimen> <regimen> bevacizumab <regimen> cetuximab
receipt of systemic corticosteroids within 3 weeks of study treatment unless patient has been taking a continuous dose of 10 mg day or less of oral prednisone or equivalent for at least 4 weeks or as part of a <regimen> prednisone taper
severe infection during second line treatment with f fc <regimen> b br meeting any 1 of the following criteria
complete 8 cycles <regimen> adjuvant chemotherapy and no recurrence metastasis occurred
adjuvant chemotherapy with <regimen> or <regimen> for more than four months 5 15 days prior recruit meet the following criteria
general status that in the opinion of the investigator does not permit the administration of eight courses of <regimen> r cpop r
treatment nave except for prior radiation or a single cycle of <regimen>
to be diagnosed as smoldering adult t cell leukemia atl the patient must have a normal lymphocyte count less than 4 times 10 3 mm 3 less than or equal to 5 percent abnormal lymphocytes on morphologic examination of the peripheral blood smear or on fluorescence activated cell sorting facs analysis cells with a homogenous staining pattern and a greater than 1 log increase in the magnitude of fluorescence emission of the anti <regimen> peak over background expression
most recent but not greater than 10 days prior to dartreg infusion 12 hour <regimen> trough levels of 8 g l for all subjects
patients who are not transplant eligible may be considered for the study following a single regimen of chemotherapy such as r <regimen> or <regimen> alone
complete metabolic remission deauville 1 3 after 6 8 cycles of r <regimen> according to the lugano criteria
patients with histological diagnosis of persistent recurrent cervical cancer local and or systemic with disease measurable by physical examination and <regimen> required confirmation by biopsy of the recurrence or persistence only if lesion is single less than 2 cm and or has no sharp edges
the patient has gastric gastroesophageal junction biliary pancreatic small bowel or colorectal cancer and has previously received the <regimen> regimen at any point in the past with evidence of disease progression within 8 weeks
<regimen> therapy is not counted as a regimen
patients who have received 1 prior treatment with il13 pe38qqr or 2 <regimen> or 3 any intracerebral investigational agent
patients must have recovered from the toxicity of prior therapy specifically there must be at least a 3 month interval from the completion of the most recent course of radiation therapy at least a 3 month interval from the implantation of <regimen> s at least a 3 week interval from the completion of a non nitrosourea containing chemotherapy regimen and at least a 6 week interval from the completion of a nitrosourea containing chemo regimen
patients who achieve only a partial response to <regimen> fludarabine cyclophosphamide and rituxan as initial therapy will be eligible
<regimen> etoposide
presence of bulky lymph nodes 5 cm after second line f fc <regimen> b br
minimum of 4 weeks since any major surgery completion of radiation or completion of all prior systemic anticancer therapy and 6 months since adjuvant <regimen> therapy adequately recovered from the acute toxicities of any prior therapy including neuropathy should be grade 1
those who are randomized to receive <regimen> methotrexate vinblastine doxorubicin and cisplatin begin <regimen> within 12 weeks after cystectomy
systemic therapy with fluorouracil leucovorin calcium oxaliplatin <regimen> and bevacizumab
women of childbearing potential and men with female partners of childbearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child while receiving treatment with guadecitabine <regimen> or ic and for at least 3 months after completing treatment
because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with tki258 or <regimen> breastfeeding should be discontinued if the mother is treated with tki258 or <regimen>
or r <regimen> infusion on cycle 1 day 1
completion of at least 3 months but no more than 7 months of standard induction chemotherapy for lapc which should consist of either <regimen> or gemcitabine and nab paclitaxel preferably with a washout period no longer than 8 weeks
patients must be considered ineligible for rituximab cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone r <regimen> standard therapy to be ineligible for r <regimen> patients must meet at least one of the following criteria are met
50 by multiple gated acquisition scan muga or cardiac echocardiogram echo prior for any patient to be treated with r <regimen>
inability to tolerate the <regimen> regimen according to investigator s judgement
10 0 g dl are shown at least 3 cycles after starting r <regimen> rituximab cyclophosphamide adriamycin vincristine prednisolone
is informed has been given ample time and opportunity to read about participation in the study and has signed and dated the written informed consent form approved by an independent ethics committee iec prior to any study related activities females 18 years histologically confirmed and documented invasive breast cancer breast cancer without evidence of distant metastases stage 4 based on staging work up chemotherapy naive who have not received chemotherapy in the neoadjuvant setting and who are candidates for chemotherapy in the adjuvant setting of taxane cyclophosphamide based regimen eg <regimen> as background chemotherapy zubrod who ecog performance status 2 adequate bone marrow hepatic and renal function reserve as evidenced by hemoglobin 10 mg dl 2
subjects must have either stage iv breast or ovarian cancer in remission or with stable disease on <regimen>
patients must have been treated with 6 or more cycles of first line <regimen> chemotherapy and have achieved a pr cru or cr patients
pregnant women are excluded from this study <regimen> is a regimen containing more than one chemotherapy agent with the potential for teratogenic or abortifacient effects
patient is eligible for low dose cytarabine <regimen> treatment
have received therapy other than r <regimen> for lymphoma
patients with transformed ctcl eligible for <regimen> regimen
subjects refractory to <regimen> as last therapy are permitted
patients who received 6 cycles of first line therapy with <regimen> or <regimen> plus bevacizumab for recurrent crc that has relapsed at least 12 months after completion of adjuvant therapy will also be included
prior to registration patients must have achieved clinical benefit with <regimen> and subsequently have systemically progressed clinical benefit is defined as having stable disease on <regimen> for at least 90 days or achieving a confirmed partial or complete response systemic progression is defined as progressive disease based on response evaluation criteria in solid tumors recist version 1 1 excluding progression based on brain cns metastases alone
patients who received 450 mg m2 doxorubicin and have a cardiac ejection fraction on echocardiogram less than or equal to 40 on protocol entry are not eligible to received <regimen> r
subject had no response ie stable disease only to first line therapy with r cyclophosphamide hydroxydaunomycin vincristine oncovin prednisone r <regimen> or an equivalent regimen
patients who received pre phase therapy for the purpose of improving performance status prior to initiating r <regimen> are eligible
organ function performance status and age suitable for an ablative regimen consisting of tbi 10gy or a chemotherapy regimen consisting of busulphan and cyclophosphamide <regimen> or busulphan and melphalan <regimen>
cardiac function does not need to be assessed in patients who will not receive doxorubicin as part of their initial therapy on this study ie patients who start on regimen <regimen>
patient had systemic chemotherapy eg sorafenib doxorubicin immunotherapy or biologic therapy or radiotherapy for hcc or treatment with <regimen> 101 5
failed flu cy cyclophosphamide rituximab <regimen> combination chemotherapy at any time point or
histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of <regimen>
hodgkin s disease patients who relapse after radiation therapy alone and previously untreated patients with stage ii bulky iii and iv who are eligible for <regimen>
histologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma colorectal adenocarcinoma gastric adenocarcinoma cholangiocarcinoma gall bladder adenocarcinoma ampullary carcinoma adenocarcinoma of unclear primary with a gastrointestinal primary suspected or other primary gastrointestinal malignancy for which the treating physician feels that <regimen> is a reasonable therapeutic option
subjects with recurrent locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after primary therapy with <regimen> or <regimen> like regimen or were intolerant of it
written informed consent male or female patient 18 years of age confirmed diagnosis of colorectal cancer chemotherapy nave patient patient scheduled to receive a <regimen> or <regimen> chemotherapy regimen according to the following scheme and dosage 1st cycle agent dose route duration days oxaliplatin or irinotecan 85 180 mg m2 i v infusion 2h 1 folinicacid leucovorin
disease progression after anthracycline and or taxane regimen therapy and candidate for <regimen> patients previously treated by capecitabine containing regimen should response to the chemotherapy containing capecitabine and progressed at least 4 months after the last capecitabine treatment karnofsky score more than 70ecog 0 2 normal functions with heart liver renal and bone marrow 8
contraindication to any drug contained in the r <regimen> chemotherapy regimen
patients who had received at least two cycles of rituximab <regimen> or <regimen> as a primary treatment patients with a history of previous exposure to hbv
medical oncologist agrees that two week window is appropriate safe prior to start of <regimen> for trial candidate
contra indication to any drug included in the <regimen> regimen
concurrent chemotherapy allowed except <regimen> therapy endocrine therapy
<regimen> <regimen> <regimen> or <regimen>
patient receiving <regimen> chemotherapy
whichever is shortest other locoregional therapy eg radiofrequency ablation rfa tace transarterial chemoembolization tare transarterial radioembolization <regimen> drug eluting bead transarterial chemoembolization
previous <regimen> treatment in the last 6 months prior to study entry
major surgical procedure open biopsy or significant traumatic injury within 28 days prior to day 1 of <regimen> bevacizumab initiation or anticipation of need for major surgical procedure during the course of the study core biopsy or other minor surgical procedure excluding placement of a vascular access device within 7 days prior to day 1 of <regimen> bevacizumab initiation history of abdominal fistula or gastrointestinal perforation within 6 months prior to day 1 of <regimen> bevacizumab initiation serious non healing wound active ulcer or untreated bone fracture proteinuria as demonstrated by
severe comorbidity that would preclude the use of <regimen> chemotherapy
cns central nervous system ascertained hypersensitivity to any component of investigational product or <regimen> bevacizumab cetuximab that the subject will be treated any of the following hematologic abnormalities hemoglobin 10 0 g dl 2
since the objective of the study is the assessment of safety eligible subjects may have any type of lymphoma hodgkin s or non hodgkin s t cell or b cell as long as the scheduled therapy is <regimen> alone
previously treated with chemotherapy regimen containing rituximab r <regimen> or r <regimen>
prior chemotherapy within the last 5 years prior rtx of the head except for low dose rtx for tinea capitis receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide prior systemic anti angiogenic therapy placement of <regimen> at surgery planned surgery for other diseases history of recent peptic ulcer disease endoscopically proven gastric ulcer duodenal ulcer or esophageal ulcer within 6 months of enrollment history of malignancy
must have relapsed or refractory chronic lymphocytic leukemia cll received no more than 5 prior myelosuppressive chemotherapy regimens and must be a candidate for treatment with either fludarabine cyclophosphamide rituximab <regimen> or bendamustine rituximab br
did not achieve at least a partial response to a standard salvage regimen eg <regimen> rituximab ifosfamide carboplatin etoposide or r <regimen> rituximab dexamethasone cytarabine cisplatin
all patients receiving treatment with <regimen> for locally advanced or metastatic nsclc either first line in patients with an activating mutation of the receptor egf r or patients with stable disease after 4 cycles of standard first line chemotherapy with platinum or after failure of at least one prior chemotherapy regimen
have previously received irinotecan or <regimen> in the metastatic setting patient is eligible if he she had received irinotecan or <regimen> as adjuvant therapy more than 6 months before entry into the study
patients with gastric or colorectal cancer stages iii or iv where a treatment with 5 fluoruracil in combination with other chemotherapeutic remedies flo <regimen> <regimen> bev <regimen> is planned
<regimen> <regimen> rgcvp high grade transformation from low grade lymphoma egfollicular lymphoma lymphoplasmacytic lymphoma chronic lymphocytic leukaemia is permitted
patients who have completed at least one dose of ipilimumab nivolumab and progress or have completed the 4 doses of ipilimumab nivolumab and progress during <regimen> maintenance are eligible unless they have received additional treatment s for their renal cell carcinoma prior to registration
patients with all stages of <regimen> expressing ctcl are eligible with the exception of stage ia
allow previous administration of up to one course of <regimen> and or fda approved tki
cisplatin r <regimen> or rituximab dexamethasone high dose cytarabine
until the initiation of round 2 <regimen> exceptions
any number of previous chemotherapy regimens except those containing tmz or dacarbazine <regimen> in the metastatic setting are allowed as long as 4 weeks have elapsed from last treatment
be designated to receive cytotoxic chemotherapy including one or more of the following agents r <regimen> <regimen> liposomal doxorubicin caelyx or liposomal daunorubicin daunoxome or paclitaxel
cyclophosphamide hydroxydaunomycin oncovin and prednisone <regimen> regimen or taxanes based regimen
<regimen> 4 oxaliplatin fluorouracil leucovorin calcium
prior treatment with 5 fu leucovorin oxaliplatin and irinotecan <regimen> treatment with any of the components as separate regimens is allowable
treatment with r <regimen> or r <regimen> like regimens transplant
to be eligible for this study patients should already be receiving a standard dose of ziv aflibercept intravenously over 60 minutes in combination with <regimen> chemotherapy every 2 weeks without evidence of progressive disease treatment on this study can start as early as two weeks from last off protocol ziv aflibercept plus <regimen> cycle granted treatment parameters have been met
a when adjuvant therapy including oxaliplatin was previously used at least 9 courses of <regimen> 2 weeks regimens 6 courses of <regimen> 3 week regimen or 750mg m 2 cumulative consumption of oxaliplatin are required
patients receiving chemotherapy other than vac <regimen> and cddp doxorubicin
prior regimens may include <regimen> bevacizumab <regimen> bevacizumab or cetuximab if kras wild type or panitumumab if kras wilt type other prior regimens may include 5 fu or capecitabine bevacizumab irinotecan cetuximab or panitumumab <regimen> ziv aflibercept or ramucirumab
any variation of <regimen> r <regimen> 14 r <regimen> 21 is acceptable
cytostatic pretreatment for b all lymphoma exceptions short term administration of steroids 7 days single administration of vincristine or cyclophosphamide one cycle of <regimen> a single administration in an emergency of other cytostatic agents for another malignant disease within the last 5 years
prior chemotherapy within the last 5 years prior rtx of the head receiving concurrent investigational agents or has received an investigational agent within the past 30 days prior to the first dose of cilengitide prior systemic antiangiogenic therapy placement of <regimen> at surgery inability to undergo gd mri
histologically confirmed adult t cell leukemia lymphoma atl or cutaneous t cell lymphoma ctcl reactivity of at least 10 of peripheral blood lymph node or dermal malignant cells with anti <regimen> as determined by immunofluorescent staining or soluble il 2 receptor level greater than 1 500 u required
confirmed free light chain complete response cr during the first three cycles of first line chemotherapy where at least the first cycle has been with cyclophosphamide bortezomib dexamethasone <regimen>
exclusion criteria history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products contraindication to any of the individual components of <regimen> including prior receipt of anthracyclines history of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer stage i without bulky patients with transformed lymphoma prior therapy for dlbcl with the exception of nodal biopsy or local irradiation previous exposure to cytotoxic agents suspect or clinical evidence of cns involvement by lymphoma 9
histologically confirmed relapsed or refractory hodgkin s disease relapsed after prior first line treatment with at least 2 regimens such as mechlorethamine vincristine procarbazine and prednisone <regimen>
patients already receiving treatment with <regimen>
wocbp must be willing to abstain from heterosexual activity or to use at least 1 highly effective method of contraception from the time of informed consent until 180 days after durvalumab and tremelimumab combination therapy is stopped or 90 days after <regimen> treatment is discontinued whichever is longer
failure of first line systemic chemotherapy with a platinum containing combination regimen consisting of <regimen> or cisplatin gemcitabine with cisplatin dosed at 60 mg m2 or higher per cycle
histologically proven advanced stage carcinoma where de gramont <regimen> or <regimen> 6 regimen is indicated
combination therapy subject is receiving methotrexate in combination with another dmard s and will require washout at entry <regimen> must have a disease
no prior rt chemotherapy including <regimen> immunotherapy or therapy with a biologic agent or hormonal therapy
must have recovered from toxicity of prior therapy at least 6 months after <regimen> at least 8 weeks after hematopoietic stem cell transplant at least 4 weeks after any cytotoxic chemotherapy or any systemic investigational agent at least 6 weeks after nitrosoureas at least 2 weeks after vincristine or non cytotoxic chemotherapy
patients subject to <regimen> therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs just for the administration of e7777 in combination with <regimen> therapy
patients aged 18 years old with advanced or metastatic solid tumor in whom standard anticancer therapies have been exhausted and who are amenable for a <regimen> according to the discretion of the principal investigators and previously treated with a cumulative dose of anthracyclines 300 mg m2
for this reason women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and up to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
diffuse large cell de novo or transformed or follicular lymphoma grade iiib stage ii iii iv according to ann arbor criteria chemoresistant disease after first line treatment <regimen> like rituximab or relapsed patients after one or two lines of chemoth
for relapsed or refractory participants recruited in obinutuzumab <regimen> regimen prior use of anthracyclines
i12 female patients must either be of non reproductive potential ie postmenopausal 12 months with no menses without an alternative medical cause or history of hysterectomy or history of bilateral tubal ligation or history of bilateral oophorectomy or must have a negative serum pregnancy test upon study entry within 72 hours before study drug start i13 fertile men with a female partner of childbearing potential must agree to use male codom plus spermicide and childbearing potential women must have agreed to use at least one highly effective contraceptive method during treatment on this trial and for up to 180 days after the last of dose of durvalumab tremelimumab or 90 days after the last dose of <regimen> whichever is the longer period i14 patient should understand sign and date the written voluntary informed consent form prior to any protocol specific procedures performed
cns metastases or carcinomatous meningitis ocular melanoma known hypersensitivity to any excipients of tracleer prior therapy with bosentan use of therapy with another investigational drug within 4 weeks of the start of dosing with bosentan or plan to receive such treatment during the study known drug or alcohol dependence or any other factor that will interfere with the conduct of the study any standard contraindications for the use of <regimen> as per australian package insert
subjects must have received at least 2 cycles of alkylator based chemotherapy to be eligible previously received rituximab either as single agent or as part of any combination regimen and also meet one of the following requirements progressed within 24 months of initiating alkylator based chemotherapy in the first line and received no additional anticancer therapy progressed within 24 months of initiating alkylator based chemotherapy in the first line and subsequently progressed within 24 months of receiving any second line treatment and received no additional anticancer therapy progressed within 24 months of initiating alkylator based chemotherapy in the second line and received no additional anticancer therapy appropriate to receive r <regimen>
the maximum tolerated dose mtd for <regimen> in patients with hepatocellular cancer was found to be 600 mg daily
any contraindication for <regimen> chemotherapy regimen
prior therapy with systemic <regimen> or conventional chemotherapy iebendamustine cvp cyclophosphamide vincristine sulfate prednisone or other rituximab for indolent non hodgkin s lymphoma nhl maintenance extended use rituximab will count as 1 line of systemic therapy
anti cancer chemotherapy radiotherapy immunotherapy or investigational agents within four weeks of first dose patients currently on <regimen> may be enrolled into the study without a washout
1 course of <regimen> doxorubicin bleomycin vinblastine and dacarbazine allowed and will be considered the first course
participants must have histologically documented diagnosis of nhl and exhausted options considered standard of care as defined in the world health organization classification scheme and relapsed following or be refractory to standard treatments such as r <regimen> <regimen> or fludarabine based regimens
de buenos aires infusion of high dose cyclophosphamide for conducting msch prior bmt gatla and <regimen> in the period 2015 2017
contraindication to any drug contained in the r <regimen> combination chemotherapy
locally advanced pancreatic adenocarcinoma patients must have received <regimen> or gemcitabine
first line in combination with <regimen> folinic acid leucovorin fluorouracil 5fu oxaliplatin or second line in combination with <regimen> folinic acid leucovorin 5fu irinotecan in subjects who have received first line fluoropyrimidine based chemotherapy excluding irinotecan for treatment of wild type ras mcrc per approved prescribing information
patients of childbearing reproductive potential should use adequate birth control measures as defined by the investigator during the study treatment period and for from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination therapy
one course of <regimen> or fractio
the effects of the combination of <regimen> and bevacizumab on the developing fetus are unknown
central radiographic review of the ct scans chest abdomen pelvis and if applicable neck from before and after first line treatment with <regimen> r fulfilling the radiological requirements for cr cru
subjects with k ras mutation positive colorectal cancer will be excluded from receiving <regimen> cetuximab
prior anti lymphoma chemotherapy except steroids radiotherapy for urgent palliation one prior cycle of <regimen> or up to 2 prior cycles of <regimen>
failed flu cyclophosphamide cy rituximab <regimen> combination chemotherapy at any time point or
treatment failure is defined as progression of disease clinical or radiologic during treatment with <regimen> with or without bevacizumab or 3 months after the last dose of treatment with <regimen> with or without bevacizumab
left ventricular ejection fraction lvef 50 by multiple gated acquisition scan muga or cardiac echocardiogram echo prior for any patient to be treated with rituximab cyclophosphamide doxorubicin vincristine prednisolone r <regimen>
presence of peripheral neuropathy grade 2 arm idelalisib nab paclitaxel and arm idelalisib <regimen>
first line chemotherapy regimen with a fluoropyrimidine and irinotecan <regimen> cetuximab with initial partial or complete response and progressive disease pd with pd 6 weeks after the last administration of cetuximab
<regimen> irb 15 011732 and or <regimen> irb
adjuvant <regimen> is permitted
inclusion criteria 1 18 age 65 relapsed refractory disease after receiving one line of standard r <regimen> like chemotherapy diffuse large b cell lymphoma at relapse
<regimen> docetaxel adriamycin cyclophosphamide
one prior cycle of <regimen> for ptcl allowed
alcl alk with ipi score less than 2 at initial diagnosis and cr after <regimen> based therapy
patients must not have prior radiation therapy chemotherapy including <regimen> immunotherapy or therapy with a biologic agent or hormonal therapy
females of childbearing potential who are sexually active with a non sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> non sterilized male partners of a female patient must use male condom plus spermicide throughout this period cessation of birth control after this point should be discussed with a responsible physician not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice however periodic abstinence the rhythm method and the withdrawal method are not acceptable methods of birth control female patients should also refrain from breastfeeding throughout this period
treatment with another chemotherapy than r <regimen> or <regimen> r
patients with metastatic disease who are eligible for first line <regimen> chemotherapy
patients must demonstrate 75 disease reduction on computed tomography ct scan confirmed by pet scan after the third cycle of <regimen> relative to baseline with no evidence of disease progression after the fifth cycle
chemotherapy combinations may include but are not limited to <regimen> cyclophosphamide doxorubicin vincristine prednisone r <regimen> rituximab cyclophosphamide doxorubicin vincristine prednisone fcm fludarabine cyclophosphamide mitoxantrone <regimen> rituximab fludarabine cyclophosphamide mitoxantrone ice ifosfamide carboplatin etoposide <regimen> dexamethasone cisplatin cytarabine and <regimen> cyclophosphamide doxorubicin vincristine dexamethasone
patients who were exposed previously to any chemotherapy except <regimen> for advanced disease
furthermore <regimen> expressing t cells may be present in the cerebrospinal fluid csf as long as the patient does not have symptomatic central nervous system cns
no other previous lymphoma therapy hormonal therapy or surgery except for standard therapy with r <regimen> with or without radiation and with or without prophylactic methotrexate therapy
fine needle aspirates are not acceptable 1 1 2 failure to submit pathology specimens within 60 days of patient registration will result in the patient being declared ineligible 1 2 institutional flow cytometry or immunohistochemistry must confirm cd20 antigen expression 1 3 patients classified as high risk according to the follicular lymphoma international prognostic index flipi should be considered for calgb 50102 swog s0016 a phase iii trial of <regimen> vs <regimen> rituximab vs <regimen> iodine 131 labeled monoclonal anti b1 antibody tositumomab
patients with a pathological or clinical diagnosis of pancreatic cancer and beginning or continuing <regimen> chemotherapy
<regimen> within 6 months of study day 1 or has not recovered from the toxic effects of such therapy
treatment failure of <regimen> cohort a or rituximab plus any concurrent or sequentially administered chemotherapy regimen cohort b for treatment of ptld
prior chemotherapy immunotherapy denileukin diftitox or investigational agent s for this lymphoma with the exception that a single cycle of <regimen> or <regimen> based therapy is allowed if the last dose of <regimen> or <regimen> based therapy was administered 28 days before study enrollment lead in or randomization main study
failed flu cyclophosphamide cy rituximab <regimen> combination chemotherapy at any time point
specifically patients receiving a regimen including both an anthracycline and a taxane are not eligible for this trial ac t ec t <regimen> etc
no prior carmustine implant <regimen>
patients must not have a limiting unresolved grade 3 or greater toxicity from <regimen> or drug intolerance preventing continuation of lenalidomide treatment
refractory is defined as failure to achieve cr or cri following 1 2 standard dose cytarabine based induction cycles or one <regimen> based cycle or failure to respond to one cycle of either standard dose or <regimen> defined as no decrease in marrow blast percentage from diagnosis on day 14 marrow or no response after at least 3 cycles of a hypomethylating agent azacytidine or decitabine
eligible third line regimens include <regimen> or irinotecan or <regimen> according to standard practice and approved indications
currently prescribed one of the following adjuvant chemotherapy regimens iv 5 fluorouracil 5 fu leucovorin lv capecitabine <regimen> 5 fu lv oxaliplatin <regimen> capecitabine and oxaliplatin
fit for full dose <regimen> as initial treatment
contraindication to any component of <regimen> regimen
2 prior cytotoxic treatments not to include belinostat <regimen> or autologous or allogeneic stem cell transplant
have failed or have not tolerated <regimen> <regimen> and if kras wild type then a egfr inhibitor based regimen
pathologically confirmed pancreatic adenocarcinoma patients with locally advanced or distant metastasis status patients who had undergone primary chemotherapy with previous <regimen> and whose disease progress was confirmed patients whose consent was obtained non insurance agreement 2
or patients who develop metastatic disease within 9 months of adjuvant <regimen> for stage ii or iii colon cancer measurable disease defined as at least 1 unidimensionally measurable lesion on a ct scan as defined by recist 1 1
patients with a history of cns involvement by lymphoma or with relapsed primary cns lymphoma will be eligible for <regimen> arm
patients relapsing within 12 months of completing adjuvant <regimen> will also be considered eligible
females who are pregnant or breastfeeding males or females of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> or 1 year after last dose of cyclophosphamide whichever is the longer time period
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or 180 days after the last dose of durvalumab tremelimumab combination
not a candidate for fludarabine cyclophosphamide rituximab <regimen> or has preference to not receive chemotherapy
operative chemotherapy combining methotrexate etoposide ifosfamide <regimen> regimen for patients 25 years doxorubicin cisplatin ifosfamide api ai regimen for patients
got non cr after <regimen> chemotherapy before imrt
first line chemotherapy with <regimen> or tmz as monotherapy group me1
ineligible for standard r <regimen> therapy
histological documentation of aggressive b cell nhl planned to receive systemic anticancer therapy with at least 6 cycles of r <regimen> 21 according to local standards 5
must have progressed on or after <regimen> in the randomized phase 2 portion of the study or progressed or experienced unacceptable toxicity on sorafenib prior to enrollment on the study
willing and able to provide written informed consent men and women 18 years of age pathologically confirmed diagnosis of her2 positive breast cancer of any stage previous treatment is allowed without limits on lines of prior therapy scheduled to receive at least 3 consecutive cycles of thp or <regimen> performance status of 0 2 according to the ecog scale negative pregnancy test at time of informed consent for women of childbearing potential able to read understand follow the study procedure and complete crofelemer rescue medication and bowel movement diaries patients may enroll simultaneously on this study and other studies including but not limited to nsabp b52 patients with brain metastases including concurrent steroid treatment are allowed on this study
subjects will be excluded from the treatment with irinotecan or <regimen> if administration of their chemotherapy would be inconsistent with the current local labeling for example in regard to contraindications warnings precautions or special provisions for that chemotherapy
has the patient elected not to undergo treatment with the <regimen> does the patient have a karnofsky performance status 70
prior enrollment on the clinical trial of <regimen> versus promace <regimen> 81 c 0166 or short course <regimen> 87 c 0180 for the treatment of previously untreated aggressive lymphomas
are contraindicated for chemoradiotherapy crt hypersensitivity or contraindication to the drug s associated with the planned choice of systemic chemotherapy <regimen> <regimen> or single agent 5 fu or capecitabine as stated in the smpc for each of the drugs
chemotherapy regimens containing <regimen> tmz and or cisplatin
failed <regimen> doxorubicin bleomycin vinblastine and dacarbazine and received salvage chemotherapy with at least 1 salvage combination regimen
3 below are eligible for the trial treatment planned to include standard <regimen> administered either every three weeks 100 mg m2 for 3 doses with concomitant radiation delivered as a continuous course of imrt with single daily fractions of 2 0 to 2 2 gy with a cumulative radiation dose between 60 gy and 72 gy
gastric cancer patients received postoprative adjuvant chemotherapy of eight cycles of <regimen>
having received a bortezomib containing regimen vtd <regimen> vrd or pad in patients with pcl for a minimum of 4 cycles with pr
subject must have relapsed following or be refractory to standard treatments such as r <regimen> <regimen> or fludarabine based regimens
patient must have received previous systemic chemotherapy usually a <regimen> like multidrug combination if not medically contraindicated with or without monoclonal antibodies and may not qualify for further conventional therapy with curative intent
excluded within the past 60 days ganciclovir foscarnet fiac fiau cmv hyperimmune globulin cmv monoclonal antibody or <regimen>
not eligible or appropriate for conventional allogeneic sct patients who achieve only a partial response to <regimen> fludarabine cyclophosphamide and rituxan as initial therapy will be eligible
patients on consolidation chemo regimens like <regimen> and <regimen> type b with expected duration of neutropenia anc 500 ml of at least 10 days
patients who are pregnant or breastfeeding or patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
failure to achieve cr within 6 months in newly diagnosed patients with intensive doxorubicin treatment relapse patients who are sensitive to doxorubicin or <regimen> chemotherapies
male or female subjects age 18 to 80 years inclusive with any international prognostic index score treated with 6 or more cycles of first line <regimen> chemotherapy and achieved a pr cru or cr
such therapies should include regimens containing oxaliplatin and irinotecan in combination with a fluoropyrimidine if appropriate eg <regimen> and <regimen> or their variants subjects that are unable to receive oxaliplatin and or irinotecan due to allergy or hypersensitivity or due to concerns regarding the side effects of oxaliplatin and or irinotecan will be allowed to receive less than two lines of standard therapies prior to enrollment to this study
at the initial stage of therapy received standard r <regimen> regimen and complete remission after the first course of treatment
<regimen> regimen or taxanes based regimen
contra indication to any drug included in the r <regimen> regimen
capecitabine and irinotecan <regimen> naive for bvz
prior radioimmunotherapy radiation therapy or any other nhl therapy except first line <regimen> r
first line treatment of dlbcl must have been 6 cycles of standard r chop21 r <regimen> or <regimen> r chemotherapy
r <regimen> given every 14 days will be excluded this should be extremely rare if at all since r <regimen> 21 is the standard treatment
patients who have started first line <regimen> therapy trastuzumab for her2 amplified tumors may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening
a priori likely to be treated by rituximab cyclophosphamide doxorubicin vincristine and prednisolone every 21 days r chop21 for 8 cycles or rituximab doxorubicin cyclophosphamide vindesine bleomycin and prednisone r <regimen>
documented completion of at least 6 cycles of <regimen> based therapy
aged 18 or above diagnosed with aegc and were prescribed with either <regimen> based or <regimen> based chemotherapy treatment
at least 6 weeks two doses must have passed since the last chemotherapy administration while in treatment with bevacizumab alone in order to consider <regimen> as maintenance therapy
patients whose therapy was switched to r <regimen> after initial treatment with r <regimen> because of aggressive disease will also be eligible for the study
colorectal cancer receiving a <regimen> regimen
female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of <regimen> or180 days after the last dose of durvalumab tremelimumab combination therapy
previous chemotherapy using oxaliplatin or alky streptozotocin dacarbazin or temozolomide other chemotherapy platin etoposide <regimen> paclitaxel or docetaxel are allowed
patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors patients eligible for second line therapy after failing first line therapy with the regimen <regimen>
histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which <regimen> irinotecan 5 fluorouracil and leucovorin treatment is appropriate
patients are allowed to have received prior treatment with <regimen> if patients are currently receiving treatment with <regimen> the subject must have documented disease progression
documented radiographic progression while on continuous treatment with <regimen>
anaplastic large cell lymphoma alcl primary systemic type excluding anaplastic lymphoma kinase positive alk with international prognostic index ipi score less than 2 at initial diagnosis and complete response cr after <regimen> based therapy
clinically fit patients to receive the <regimen> chemotherapy scheme
eligible patients will have stable disease on <regimen> at fda approved doses after a minimum duration of erlotinib therapy of 2 months
subject must have relapsed following or be refractory to 1 standard treatments such as r <regimen> <regimen> bendamustine lenalidomide rituximab or fludarabine based regimens
patients who were administered 4 6 cycles of cisplatin based first line chemotherapy gp gemcitabine cisplatin classic <regimen> methotrexate vinblastine doxorubicin cisplatin or dose dense <regimen> and were planned to undergo regular surveillance 4
e 28 evidence of any other disease metabolic dysfunction physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications e 29 female patients who are pregnant or breastfeeding or male or female patients of reproductive potential 2 years after last menstruation and not surgically sterile who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab tremelimumab combination therapy or 90 days after the last dose of <regimen> whichever is the longer time period
patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with <regimen> vincristine prednisolone daunorubicin l asparaginase <regimen> cyclophosphamide vincristine prednisolone daunorubicin l asparaginase or r <regimen> rituximab cyclophosphamide vincristine adriamycin dexamethasone
inclusion criteria patients with a diagnosis of all ll or burkitt s receiving induction chemotherapy with <regimen> any variant of <regimen> or augmented bfm at md anderson cancer center
previous treatment with <regimen> or tmz
cd20 positive b cell non hodgkin s lymphoma treatment with rituximab and <regimen> or cop performance status 0 or 1 according to the who scale appendix
patients with advanced adenocarcinoma of the colon or rectum not curable with surgery or radiotherapy and have been previously treated for their disease with <regimen> plus bevacizumab in the first line metastatic setting
disease not amenable to curative or transplant surgery bclc stage b disease must be reviewed by members of disease management team at the local enrolling institution and be amenable to <regimen> to treat all sites of disease in one session
patients who are going to receive <regimen> or chase treatment regimen
women of childbearing potential must have a pregnancy test performed a maximum of 7 days before start of <regimen> treatment and a negative result must be documented before start of treatment
planned for first line systemic therapy with <regimen> or gp either in routine care or in combination with an investigational agent s within a clinical trial
excluded prior therapies include prior high dose aldesleukin sorafenib and <regimen>
patients affected by gastrointestinal cancer without cytotoxic neurotoxic chemotherapy had to receive <regimen> 4 chemotherapy folinic acid 5 fu oxaliplatin in the adjuvant neoadjuvant or palliative situation with an expected period of 8 cures of treatment or 4 months
for subjects receiving doxorubicin no concurrent use of inhibitors and inducers of cyp3a4 cyp2d6 and or p gp or with trastuzumab due to increased risk of cardiac dysfunction chemotherapy other than that included in this study taxane cyclophosphamide based regimen eg <regimen> or tc or neoadjuvant chemotherapy or known immunosuppressive agents including chronic oral corticosteroid use or radiation therapy within 4 weeks of first dose of hsp 130 prior bone marrow or stem cell transplantation or malignancy within 5 years known her2 overexpressing breast cancer
disease relapse within 12 months after completing therapy with a regimen containing flu or another nucleoside analog 2 failed flu cyclophosphamide cy rituximab <regimen> combination chemotherapy at any time point or 3 have 17p deletion cytogenetic abnormality patients should have received induction chemotherapy but could be transplanted in 1st cr or 4 patients with a diagnosis of cll or small lymphocytic lymphoma or diagnosis of cll that progresses to prolymphocytic leukemia pll or t cell cll or pll 5 patients failing to achieve a response to ibrutinib as first line therapy 6 patients not responding to ibrutinib idelalisib or venetoclax as salvage therapy or intolerant of these agents as salvage therapy due to side effects all cll patients must have received prior myelosuppressive chemotherapy
have discontinued from first line treatment with <regimen> for any reason ie tumor disease progression intolerance at least 14 days prior to planned randomization but have not received any second line treatment for hcc
patients must have a mri consistent with a who grade iv primary malignant glioma glioblastoma multiforme or gliosarcoma and be candidates for surgical resection with <regimen> placement
for patients who receive first line <regimen> or sorafenib based combination patients must have received at least 14 days of sorafenib treatment with the lowest dosage of 400 mg per day
previous or current malignant tumor beyond hcc allergy to any agent of the <regimen> regimen history of organ transplantation previously receiving other treatments for hcc pregnant or breastfeeding women and women of childbearing potential without adequate contraception neurological or mental abnormalities that may affect cognitive assessment and inform consent concomitant anti tumor therapy or participating in other interventional clinical trials other psychological family or social reason which would affect compliance with the study protocol
patients may not have had previous treatment with a <regimen> or temozolomide based chemotherapy regimen
inclusion criteria patients with any type of relapsed or refractory b cell lymphoma eligible to receive <regimen> or <regimen> regarding the investigator s opinion who received prior therapy with at least one but no more than two lines therapies for b cell lymphoma patient
planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever including but not limited to r <regimen> <regimen> and r <regimen> <regimen> and smile
histologically proven gbm which is recurrent or progressive following surgery or biopsy external beam radiation therapy and 1 previous regimen of systemic chemotherapy <regimen> therapy is not considered systemic chemotherapy malignancy is to be documented with a previous histopathological report
exclusion criteria types of multiple myeloma previously shown to be irresponsive to <regimen> during the last 6 months plasma cell leukemia subject with positive hepatitis panel including hepatitis b surface antigen hbsag and or anti hepatitis b core antibodies and or hepatitis c virus antibody anti hcv and or a positive hiv antibody screen severe abnormal organ function function or laboratory results at the time of the screening visit
patients ages 22 24 will only be enrolled if they are currently being treated at <regimen> or another pediatric facility oncologist expected survival 12 weeks creatinine 2 5 mg dl and less than 2 5x normal for age 5
